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ABSTRACT 
DESIGN AND DEVELOPMENT OF REDOX-RESPONSIVE NANOCARRIERS FOR 
THERAPEUTIC DELIVERY 
MAY 2018 
PRIYAA PRASAD, B. TECH, INSTITUTE OF CHEMICAL TECHNOLOGY MUMBAI 
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Sankaran Thayumanavan 
 Biologically active agents like drugs, proteins and nucleic acids have been widely explored 
as therapeutics for numerous diseases and particularly for anti-cancer therapy. Delivering drugs, 
proteins and nucleic acids efficiently and safely is however the looming challenge in the field of 
chemical biology. A significant percentage of drugs are poorly water-soluble which affects its 
pharmacological properties for instance bioavailability, stability and dose dependent toxicity. Drug 
development and discovery is a time consuming and expensive process which typically takes more 
than a decade and costs more than 10 million dollars. Nucleic acids are also known to degrade 
rapidly by nucleases. Therapeutic delivery using a delivery vehicle is realized to be advantageous 
in many fronts.  
Delivery vehicles, specifically nanocarriers improve the physiochemical properties of 
conventional drugs like water solubility, biodistribution, reduce dose dependent toxicity, 
bioavailability and help in targeting.  For nucleic acids, they essentially protect it from degradation 
and aid in intracellular transfection. Polymeric nanocarrier systems show superior characteristics 
as therapeutic delivery vehicles. Polymers are extremely versatile in terms of synthesis, 
incorporating reactive functional groups for stimuli responsive behavior and facile tunability of 
hydrophobic and/or hydrophilic segments for structure property relationship.  Self-crosslinked 
		
	
viii 
polymeric nanocarriers developed in our group have shown important properties for therapeutic 
delivery like redox responsive release mechanism, size tunability, encapsulation stability etc. We 
have utilized this system as the blueprint and developed it to improve and address some crucial 
properties of drug delivery vehicles. We designed a crosslinked polymeric nanogel system 
composed of molecules that are approved by the FDA as safe and non-toxic.  The nanogels were 
found to be highly non-toxic when evaluated by in vitro cell viability assay and a more rigorous 
mouse pre-implantation embryo toxicity assay.  We were also interested to tackle the issue of poor 
drug loading capacity of nanocarriers and designed a core crosslinked polymer and designed 
methods to quantify drug loading in crosslinked polymeric systems where we were also curious in 
studying the structure property relationship of different drugs with varying LogP values. Lastly, 
we designed a safe delivery system for nucleic acids which utilizes the cationic charge in the 
polymer for complexation with nucleic acid but through convenient crosslinking strategy we could 
eliminate the charged moieties making it a promising strategy for nucleic acid delivery  
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1 
CHAPTER 1 
INTRODUCTION: TOWARDS DEVELOPING DELIVERY VEHICLES 
Progress in medicinal chemistry, science and technology has led to the discovery of many 
drugs that has benefited mankind. However, there are still diseases like cancer that do not have a 
definite cure. Discovering and developing a new therapeutic drug involves processes such as target 
validation, pre-clinical testing, clinical testing, regulatory challenges etc. The entire course 
typically takes over a decade and costs over 100 million dollars.1–3 Administration of free, active 
drug has many drawbacks – i) poor solubility, ii) toxicity which stems from using formulation 
vehicles for drugs, such as Crempher (for Paclitaxel), iii) tissue damage due to extravasation iv) 
loss in drug activity- for instance, Camptotheicin loses 90% of its activity 30 minutes after 
administration, v) rapid clearance of the free drug by the kidney, and vi) lack of selectivity for the 
target.4–7 The complications of using free drugs and the expensive and time-consuming process of 
drug development and discovery has led to the research and development of drug delivery vehicles 
which can improve drug solubility thus reducing the dose dependent toxicity, improve the drug 
half-life by shielding it and improve the pharmacological properties.8–10 
 
 
		
	
2 
 
 
1.1 Carriers for drug delivery 
1.1.1 Polymer-drug conjugate 
Ringsdorf in 1975 put forth a polymer-drug model which uses different segments of the 
block copolymer or terpolymer for introducing distinctive properties like solubility, drug 
attachment and transportation.11 This approach overcomes several drawbacks of administering the 
free active drug like improved solubility after conjugation with a water-soluble polymer which 
improves bioavailability and reduces the effect of dose dependent toxicity. Several targeting 
moieties can be attached to the polymer-drug conjugate which again reduces the off-target side 
effect of anticancer drugs.12–15 There are several polymer-drug conjugates approved by the FDA 
for pre-clinical and clinical use; for e.g. OPAXIO™ (formerly branded as XYOTAX), which is a 
conjugate of poly (L-glutamic acid) is currently in Phase III clinical trial. Polymer-drug conjugates 
however have some downsides like low drug loading capacity, inactivity of the attached drug, and 
since polymer-drug conjugate is considered a new chemical moiety, it must undergo the routine 
Figure 1. 1 Historical timeline of major developments in the field of cancer nanomedicine. 
(reproduced with permission from reference)10 
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regulatory evaluations. 16 Carriers which utilize the non-covalent approach for drug delivery will 
be discussed in the following section. 
 
 
 
 
1.1.2 Liposomes 
 Since the pioneering discovery in the 1960’s by late Alec Bangham and colleagues on 
phospholipid bilayer structure of the cell membrane, there has been a tremendous interest and 
research on liposomes.17 Liposomes are vesicles that are composed of an aqueous core and a 
hydrophobic membrane comprising of phospholipids for e.g.  phospatidylocholine. Owing to this 
structural make up, both hydrophilic and hydrophobic guests can be encapsulated in liposomes. 18–
20 Liposomes were the first nanocarriers to be translated to clinical use owing to its 
biocompatibility, and currently they are the most widely accepted in clinical trials for various 
diseases, majorly for cancer. The major disadvantage of liposomes is its chemical and physical 
Figure 1. 2 Schematic representation 
of polymer dug conjugate model. 
(Reprinted with permission from 
reference 15) 
		
	
4 
instability. 21-22 They are known to fuse with other vesicles forming larger aggregates. They are 
also known to have poor encapsulation efficiency.  
 
 
1.1.3 Dendrimers 
 The word dendrimer is derived from the Greek word ‘Dendron’ which is synonymous to a 
tree. Technically, dendrimers are monodisperse, branched macromolecules that are typically in the 
molecular weight range of 5000-500,000 g/mol. They structurally consist of a multifunctional core, 
branched moieties and surface functional units.23–25 There are two synthetic approaches for 
dendrimer synthesis. In the divergent approach pioneered by Tomalia, a multifunctional core is 
utilized to react with reactive monomers outwards.26-27 In the convergent method pioneered by 
Hawker and Frechet, the reactive monomer ends up in the surface and the dendrimer is built 
inwards.28-29 Another class of dendrimers known as facially amphiphilic dendrimers first reported 
by our group in 2001 consist of hydrophobic and a hydrophilic moiety in each repeat unit 
orthogonal to each other by introducing biaryl building blocks.30-31 Amphiphilic dendrimers are 
capable of encapsulating hydrophobic guest molecules. Some of the widely studied dendrimers are 
polyamidoamine (PAMAM), poly (propylene imine) (PPI) and poly-L-lysine. The major 
Figure 1. 3 Schematic representation of 
liposome. (Reprinted with permission from 
reference 19) 
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disadvantages of these dendrimers are firstly the cytotoxicity associated with the charged surface 
which is dependent on the number of generations (branching repeat units) and secondly the 
challenging and laborious synthesis.  
 
 
 
 
 
1.1.4 Polymeric micelle 
 Polymers that have both hydrophobic and hydrophilic moieties that can self-assemble to 
form micelle like aggregates in aqueous solution are known as polymeric micelles. Polymeric 
micelles are attractive in the field of drug delivery mainly because they are easy to synthesize and 
can be highly versatile in terms of the length and structure of the hydrophobic or hydrophilic 
Figure 1. 4 Schematic showing orthogonal placement of 
amphiphilic units in each layer of the facially amphiphilic 
dendron. (b) Example of a facially amphiphilic G2 dendron. 
(reproduced with permission from reference 28, 
http://pubs.acs.org/doi/10.1021/ar500143u). Further 
permissions related to the material excerpted should be 
directed to the ACS. 
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moieties. These are extremely critical properties that can dictate the size of the assemblies that 
indirectly influence the targeting properties and the loading efficiencies.32-33 There has been a lot 
of effort in utilizing polymeric micelles for clinical translation. There are many polymeric micelle 
systems in clinical trials for cancer therapy. Paclitaxel-loaded PEG-b-PLA called Cynviloq™ 
which was recently licensed by Sorrento Therapeutics Inc. reached Phase III clinical trial.34 Since 
the formation of micelle and its stability are concentration dependent, strategies like chemical 
crosslinking the micelles can improve its stability against disassembly and improve the drug 
encapsulation stability in vivo.  
1.1.5 Core crosslinked polymeric micelles 
 Chemically crosslinking the hydrophobic core of polymeric micelles is a useful strategy 
employed to improve the stability of micelle formation against disassembly as crosslinking 
eliminates the equilibrium limitation between unimers and micelles. Some of the common 
crosslinking strategies employed are through bifunctional crosslinkers, disulfide exchange or 
radical polymerization.35–37 In our lab, we have established a core crosslinked nanogel system 
which showed stable hydrophobic guest encapsulation. It was also shown that the encapsulation 
stability and the release kinetics of the guest could be tuned by varying the crosslink density.38-39 
Since stable encapsulation and prevention of premature drug release are important properties of a 
drug delivery vehicle, core crosslinked polymeric micelles show great potential for in vivo 
applications in drug delivery.  
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1.2 Characteristics of a drug delivery vehicle 
 Developing and designing new drug delivery methods is an advancing field. After decades 
of research on drug delivery systems, many key issues associated with targeted and controlled drug 
delivery for clinical applications have been identified. The successful design of an efficient drug 
delivery system will depend on the synergistic implementation of key properties like target 
specificity, mechanism for drug release, high drug loading capability, biocompatibility and 
biodegradability.  
 
 
Figure 1. 5 Schematic representation of the formation of redox 
responsive nanogels. (Reprinted with permission from reference 
36). Copyright © 2010 American Chemical Society. 
Figure 1. 6 Pictorial representation of the ideal 
characteristics of a drug delivery carrier 
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1.2.1 Responsiveness to stimuli 
 One of the strategies to increase drug accumulation in the diseased site and thereby 
increasing the therapeutic index of the drug is using stimuli responsive systems. Introducing 
stimuli responsive functional groups in the nanocarriers facilitates on demand release of the drug. 
Blumenthal et al conceptualized stimuli responsive drug release in thermo-responsive liposomes 
in the 1970’s.40 Over the past decade there has been significant research in the field of stimuli 
responsive nanocarriers for drug delivery. The stimuli that are exploited for drug delivery can be 
categorized into externally and internally regulated stimuli. Stimuli that are applied from outside 
the body are called external stimuli. These include ultrasound,41–43 temperature,44–46 magnetic 
field,47-48 light etc.49-50 External stimuli are easy to regulate however there is still research needed 
to improve the penetration of some stimuli like light and ultrasound into the diseased site. Internal 
stimuli are the ones that are present inside the body and include pH,51-52 redox,53–55 enzymes etc.56-
57 Diseased sites are often accompanied by changes in pH, enzymes etc., and hence utilizing 
internal stimuli for drug delivery becomes important and relevant.  
1.2.2 High drug loading capacity 
 Most nanocarriers used for drug delivery show poor drug loading with loading capacities 
less than 10%.58 This would necessitate a higher dosage of nanocarrier to attain the same 
therapeutic effect of the drug which would further require increasing the number of intravenous 
injections. Using higher amount of nanocarriers also increases the systemic toxicity associated 
with it. Additionally, there is also toxicity stemming from poor nanocarrier clearance from the 
body. These factors eventually fall out of patient compliance.   Using nanocarriers with high drug 
loading capacity has the potential to moderate toxicity issues and is line with patient compliance. 
This property of nanocarriers becomes critical for clinical translations. 
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1.2.3 Target specificity 
 Targeting refers to the ability of drug delivery carriers to target the diseased tissues. 
Targeted delivery can be achieved by nanocarriers through passive or active targeting.59 Passive 
targeting exploits the pathophysiology of tumors to help nanocarriers accumulate by the EPR 
effect. Maeda in 1989 coined the term ‘enhanced permeability and retention (EPR)’ effect caused 
due to the increased permeability of the nanocarriers about the size range of 10 - 500 nm due to 
leaky blood vessels and poor lymphatic drainage of the tumors.60 
 Active targeting involves the usage of targeting ligands which are selective for a specific 
receptor available at the target site. Active targeting improves the EPR effect in targeting specific 
cells in the tumor tissue. Ligands like peptides, antibodies, aptamers and other small molecules 
have been utilized for active targeting.61-62 This improves the biodistribution of the drug, thus 
improving the therapeutic index and reducing side effects. 
 
 
Figure 1. 7 Passive and active targeting strategies of nanoparticles 
for cancer therapy. (Reprinted with permission from reference 57) 
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1.2.4 Biocompatibility and Biodegradability 
 Polymers that can be degraded hydrolytically or enzymatically are generally known as 
biodegradable polymers. Biodegradable polymers are either degraded to non-toxic components or 
to molecules that can be cleared from the body through metabolic pathway.63 For polymers that do 
not contain a target specific, stimuli responsive functional group, biodegradability provides a 
mechanism for sustained release of the drug which improves its bioavailability and thus its 
therapeutic index. Naturally occurring biopolymers like collagen have been used in the biomedical 
field for thousands of years.64-65  
 Biopolymers possess an essential property of biological recognition. However, these lack 
a good control over material properties, and purification.66  They also lack the desired optimization 
required to interface with biological systems.  On the other hand, synthetic biodegradable polymers 
have gained increased interest since the late 20th century. These can be synthesized with adjustable 
properties. Polymers based on lactic acid and glycolic acid have been comprehensively studied 
and used for biomedical applications because of their hydrolytic degradation property. Synthetic 
biodegradable polymers can be prepared by introducing hydrolytically unstable bonds in the 
backbone of the polymer. Some of the most common functional groups susceptible to hydrolysis 
are esters, amides and anhydrides.66 Synthetic biodegradable polymers have been extensively 
studied for drug delivery applications because of their low cellular toxicity, biocompatibility, ease 
of synthesis and purification. Some examples are as follows 67 - 
i. Polyesters like poly (lactic acid), poly (glycolic acid), poly (hydroxy butyrate), poly (ε- 
caprolactone), poly (β-malic acid), poly(dioxanones). 
ii. Polyamides like Poly (imino carbonates), poly (amino acids) 
iii. Phosphorous-based polymers like Polyphosphates, polyphosphonates, 
polyphosphazenes 
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 It is important that along with the polymer being biodegradable, they are biocompatible. 
Biocompatibility is an important physiochemical property that the nanocarrier must possess to 
avoid systemic toxicity and clearance from the body.  When nanocarriers enter the bloodstream, 
they are recognized by the phagocytic cells as foreign objects and are removed from circulation 
through a process called opsonization.68 Polyethylene glycol is popularly used to decorate the 
surface of nanocarriers to avoid recognition by the phagosomes as they are hydrophilic and form 
a protective shell around the nanocarrier.69-70 There are other factors that need to be considered to 
prevent an immune response from the macrophages. For instance, size and surface properties like 
charge are shown to affect the immune response. It becomes crucial to design the nanocarriers in 
such a way that they are protected from being recognized by phagocytic cells and increase their 
circulation time and bioavailability.  
1.3 Nucleic acid delivery  
 Nucleic acids are important biomacromolecules that contain genetic information in living 
organisms. Along with transferring the genetic information from one generation to another, they 
perform the vital function of synthesizing proteins that is essential for the basic functioning of all 
living organisms. Nucleic acids are composed of nucleotides that each contain a nitrogenous base 
- Adenine, Guanine, Cytosine, and Thymine/Uracil, a 5-carbon sugar and a phosphate group.  
There are many diseases that are caused by gene mutations. After the completion of the human 
genome project in 2013, the genetic information that was gathered has helped us understand the 
molecular mechanisms that govern diseases that are caused by gene modification.71 Gene therapy 
is utilizing nucleic acids as drugs to treat diseases that are caused by gene modifications. The 
different approaches for gene therapy include replacing defective genes with a healthy copy, 
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knocking down defective genes or overexpressed genes and inserting new genes that can help fight 
a disease. 
Naked nucleic acids however are prone to rapid degradation by nucleases in the body and hence 
there has been a lot of research to develop delivery vehicles for nucleic acid.72  
1.3.1 Viral vectors 
 Viral vectors are the most efficient in transfecting nucleic acids because of their evolved 
mechanism of invading cells. More than 65% of the gene therapy clinical trials use viral vectors.73 
The different types of viral vectors used are lentiviruses, retroviruses and adenoviruses. However, 
they show poor loading capabilities and the repeated administration of virus causes 
immunogenicity risks.74-75  
1.3.2 Non-viral vectors 
 Cationic dendrimers, cationic polymers, liposomes, cell penetrating peptides etc. are 
widely studied as non-viral vectors for gene therapy.74-75 Cationic delivery vehicles form an 
electrostatic complex with the negatively charged phosphate backbone of nucleic acids. Cationic 
polymers have been widely explored for gene delivery because of its many advantages like easy 
and inexpensive synthesis, high loading capabilities and moderate transfection efficiency but there 
is cytotoxicity associated with the high density of cationic charge.74-75 The focus of gene delivery 
worldwide has been to develop a safe delivery method which shows good transfection efficiency.  
1.4 Thesis overview 
 This thesis work focuses on designing polymeric nanocarriers that addresses and improves 
the properties of drug and nucleic acid delivery systems viz. biocompatibility, high drug loading 
capacity and cytotoxicity. In chapter 2 we have designed polymeric nanocarrier that is composed 
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of components that are made out of GRAS materials. GRAS is an acronym for Generally 
Recognized as Safe, a term coined by the FDA for molecules that are safe to be used as food 
additives or in packaging and medical devices. The nanocarrier is target specific, stimuli 
responsive due to the disulfide crosslinks and non-cytotoxic. The non-cytotoxicity was shown by 
the in vitro viability assays and a vigorous preimplantation mouse embryo analysis which is 
considered a very sensitive assay to evaluate toxicity of materials.  
 In Chapter 3 we developed a nanocarrier system that addresses the issue of drug loading 
capacity. We also developed methods to quantify drug loading in chemically crosslinked 
polymeric systems. The crosslinked nanogel system based on block copolymer shows high drug 
loading values and high in vitro cell killing efficiencies.  
 In Chapter 4 we designed a polymeric system for delivering nucleic acids. The design uses 
cationic charge to form a complex with the negatively charged nucleic acid, and following 
complexation, we chemically crosslink the complex which reduces the cationic charge density of 
the crosslinked complex. We demonstrate that the polymer can successfully form a stable complex 
with siRNA and the crosslinked complex is responsive to higher concentrations of Glutathione 
which is typically found in the cytosol. 
1.5 References 
1. Tiwari, G.; Tiwari, R.; Bannerjee, S.; Bhati, L.; Pandey, S.; Pandey, P.; Sriwastawa, B. 
Drug Delivery Systems: An Updated Review. Int. J. Pharm. Investig., 2012, 2, 2–11. 
2. Van Norman, G.A. Drugs, Devices, and the FDA: Part 1: An Overview of Approval 
Processes for Drugs. JACC Basic to Transl. Sci., 2016, 1, 170–179. 
3. The Drug Development and Approval Process: FDAReview.org. 
http://www.fdareview.org/03_drug_development.php (Accessed Jan 17, 2018). 
		
	
14 
4. Allen, T.M.; Cullis, P.R. Drug Delivery Systems : Entering the Mainstream. Science (80-. 
)., 2014, 303, 1818–1823. 
5. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The Drawbacks 
and Advantages of Vehicle Selection for Drug Formulation. Eur. J. Cancer, 2001, 37, 
1590–1598. 
6. Goolsby, T. V.; Lombardo, F.A. Extravasation of Chemotherapeutic Agents: Prevention 
and Treatment. Semin. Oncol., 2006, 33, 139–143. 
7. Danesi, R.; De Braud, F.; Fogli, S.; Di Paolo, A.; Del Tacca, M. Pharmacogenetic 
Determinants of Anti-Cancer Drug Activity and Toxicity. Trends Pharmacol. Sci., 2001, 
22, 420–426. 
8. Rosen, H.; Abribat, T. The Rise and Rise of Drug Delivery. Nat. Rev. Drug Discov., 2005, 
4, 381–385. 
9. Wertheimer, A.I.; Santella, T.M.; Finestone, A.J.; Levy, R.A. Drug Delivery Systems 
Improve Pharmaceutical Profile and Facilitate Medication Adherence. Adv. Ther., 2005, 
22, 559–577. 
10. Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer Nanomedicine: Progress, 
Challenges and Opportunities. Nat. Rev. Cancer, 2016, 17, 20–37. 
11. Ringsdorf, H. Structure and Properties of Pharmacologically Active Polymers. J. Polym. 
Sci. Polym. Symp., 2007, 51, 135–153. 
12. Zhou, P.; Li, Z.; Chau, Y. Synthesis, Characterization, and in Vivo Evaluation of 
Poly(ethylene Oxide-Co-Glycidol)-Platinate Conjugate. Eur. J. Pharm. Sci., 2010, 41, 
464–472. 
13. Van, S.; Das, S.K.; Wang, X.; Feng, Z.; Jin, Y.; Hou, Z.; Chen, F.; Pham, A.; Jiang, N.; 
		
	
15 
Howell, S.B.; Yu, L. Synthesis, Characterization, and Biological Evaluation of poly(L-γ-
Glutamyl-Glutamine)- Paclitaxel Nanoconjugate. Int. J. Nanomedicine, 2010, 5, 825–837. 
14. Larson, N.; Ghandehari, H. Polymeric Conjugates for Drug Delivery. Chem. Mater., 2012, 
24, 840–853. 
15. Pasut, G.; Veronese, F.M. Polymer–drug Conjugation, Recent Achievements and General 
Strategies. Prog. Polym. Sci., 2007, 32, 933–961. 
16. Duncan, R. The Dawning Era of Polymer Therapeutics. Nat. Rev. Drug Discov., 2003, 2, 
347–360. 
17. Deamer, D.; Bangham, A.D. Large Volume Liposomes by an Ether Vaporization Method. 
Biochim. Biophys. Acta - Biomembr., 1976, 443, 629–634. 
18. Discher, D.E.; Eisenberg, A. Polymer Vesicles. Science (80-. )., 2002, 297, 967–974. 
19. Torchilin, V.P. Recent Advances with Liposomes as Pharmaceutical Carriers. Nat. Rev. 
Drug Discov., 2005, 4, 145–160. 
20. Cordon, C.S.; Piva, M.B.R.; Melo, C.M.; Pinhal, M.A.S.; Saurez, E.R. Nanoparticles as 
Platforms of Molecular Delivery in Diagnosis and Therapy. OA Cancer , 2013, 1, 1–6. 
21. Mozafari, M.R. Liposomes: An Overview of Manufacturing Techniques. Cell. Mol. Biol. 
Lett., 2005, 10, 711–719. 
22. Akbarzadeh, A.; Rezaei-sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N. Liposome : 
Classification , Preparation , and Applications. Nanoscale Res. Lett., 2013, 8, 1–9. 
23. Madaan, K.; Kumar, S.; Poonia, N.; Lather, V.; Pandita, D. Dendrimers in Drug Delivery 
and Targeting: Drug-Dendrimer Interactions and Toxicity Issues. J. Pharm. Bioallied Sci., 
2014, 6, 139–150. 
24. Lee, C.C.; MacKay, J.A.; Fréchet, J.M.J.; Szoka, F.C. Designing Dendrimers for 
		
	
16 
Biological Applications. Nat. Biotechnol., 2005, 23, 1517–1526. 
25. Qin, Y. Alginate Fibers: An Overwiew of the Production Processes and Applications in 
Wound Management. Polym. Int., 2008, 57, 171–180. 
26. Tomalia, D.A. Starburst Dendrimers - Nanoscopic Supermolecules according to Dendritic 
Rules and Principles. Macromol.Symp, 1996, 101, 243–255. 
27. Esfand, R.; Tomalia, D.A. Poly(amidoamine) (PAMAM) Dendrimers: From Biomimicry 
to Drug Delivery and Biomedical Applications. Drug Discovery Today, 2001, 6, 427–436. 
28. Frechet, J.M. Functional Polymers and Dendrimers: Reactivity, Molecular Architecture, 
and Interfacial Energy. Science (80-. )., 1994, 263, 1710–1715. 
29. Grayson, S.M.; Fréchet, J.M.J. Convergent Dendrons and Dendrimers: From Synthesis to 
Applications. Chem. Rev., 2001, 101, 3819–3867. 
30. Raghupathi, K.R.; Guo, J.; Munkhbat, O.; Rangadurai, P.; Thayumanavan, S. 
Supramolecular Disassembly of Facially Amphiphilic Dendrimer Assemblies in Response 
to Physical, Chemical, and Biological Stimuli. Acc. Chem. Res., 2014, 47, 2200–2211. 
31. Klaikherd, A.; Sandanaraj, B.S.; Vutukuri, D.R.; Thayumanavan, S. Comparison of 
Facially Amphiphilic Biaryl Dendrimers with Classical Amphiphilic Ones Using Protein 
Surface Recognition as the Tool. J. Am. Chem. Soc., 2006, 128, 9231–9237. 
32. Torchilin, V.P. Micellar Nanocarriers: Pharmaceutical Perspectives. Pharm. Res., 2007, 
24, 1–16. 
33. Jones, M.; Leroux, J. Polymeric Micellesea New Generation of Colloidal Drug Carriers. 
Eur J PharmBiopharm, 1999, 48, 101–111. 
34. Shin, D.H.; Tam, Y.T.; Kwon, G.S. Polymeric Micelle Nanocarriers in Cancer Research. 
Front. Chem. Sci. Eng., 2016, 10, 348–359. 
		
	
17 
35. Talelli, M.; Barz, M.; Rijcken, C.J.F.; Kiessling, F.; Hennink, W.E.; Lammers, T. Core-
Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and 
Clinical Translation. Nano Today, 2015, 10, 93–117. 
36. van Nostrum, C.F. Covalently Cross-Linked Amphiphilic Block Copolymer Micelles. Soft 
Matter, 2011, 7, 3246. 
37. O’Reilly, R.K.; Hawker, C.J.; Wooley, K.L. Cross-Linked Block Copolymer Micelles: 
Functional Nanostructures of Great Potential and Versatility. Chem. Soc. Rev., 2006, 35, 
1068. 
38. Ryu, J.-H.; Chacko, R.T.; Jiwpanich, S.; Bickerton, S.; Babu, R.P.; Thayumanavan, S. 
Self-Cross-Linked Polymer Nanogels: A Versatile Nanoscopic Drug Delivery Platform. J. 
Am. Chem. Soc., 2010, 3, 17227–17235. 
39. Chacko, R.T.; Ventura, J.; Zhuang, J.; Thayumanavan, S. Polymer Nanogels: A Versatile 
Nanoscopic Drug Delivery Platform. Adv. Drug Deliv. Rev., 2012, 64, 836–851. 
40. Yatvin, M.; Weinstein, J.; Dennis, W.; Blumenthal, R. Design of Liposomes for Enhanced 
Local Release of Drugs by Hyperthermia. Science (80-. )., 1978, 202, 1290–1293. 
41. Schroeder, A.; Honen, R.; Turjeman, K.; Gabizon, A.; Kost, J.; Barenholz, Y. Ultrasound 
Triggered Release of Cisplatin from Liposomes in Murine Tumors. J. Control. Release, 
2009, 137, 63–68. 
42. Rapoport, N.Y.; Kennedy, A.M.; Shea, J.E.; Scaife, C.L.; Nam, K.H. Controlled and 
Targeted Tumor Chemotherapy by Ultrasound-Activated Nanoemulsions/microbubbles. J. 
Control. Release, 2009, 138, 268–276. 
43. Kheirolomoom, A.; Mahakian, L.M.; Lai, C.Y.; Lindfors, H.A.; Seo, J.W.; Paoli, E.E.; 
Watson, K.D.; Haynam, E.M.; Ingham, E.S.; Xing, L.; Cheng, R.H.; Borowsky, A.D.; 
		
	
18 
Cardiff, R.D.; Ferrara, K.W. Copper-Doxorubicin as a Nanoparticle Cargo Retains 
Efficacy with Minimal Toxicity. Mol. Pharm., 2010, 7, 1948–1958. 
44. Tagami, T.; Foltz, W.D.; Ernsting, M.J.; Lee, C.M.; Tannock, I.F.; May, J.P.; Li, S.D. 
MRI Monitoring of Intratumoral Drug Delivery and Prediction of the Therapeutic Effect 
with a Multifunctional Thermosensitive Liposome. Biomaterials, 2011, 32, 6570–6578. 
45. Zhang, J.; Chen, H.; Xu, L.; Gu, Y. The Targeted Behavior of Thermally Responsive 
Nanohydrogel Evaluated by NIR System in Mouse Model. J. Control. Release, 2008, 131, 
34–40. 
46. Al-Ahmady, Z.S.; Al-Jamal, W.T.; Bossche, J. V.; Bui, T.T.; Drake, A.F.; Mason, A.J.; 
Kostarelos, K. Lipid-Peptide Vesicle Nanoscale Hybrids for Triggered Drug Release by 
Mild Hyperthermia in Vitro and in Vivo. ACS Nano, 2012, 6, 9335–9346. 
47. Plassat, V.; Wilhelm, C.; Marsaud, V.; Ménager, C.; Gazeau, F.; Renoir, J.M.; Lesieur, S. 
Anti-Estrogen-Loaded Superparamagnetic Liposomes for Intracellular Magnetic Targeting 
and Treatment of Breast Cancer Tumors. Adv. Funct. Mater., 2011, 21, 83–92. 
48. Hua, M.Y.; Liu, H.L.; Yang, H.W.; Chen, P.Y.; Tsai, R.Y.; Huang, C.Y.; Tseng, I.C.; 
Lyu, L.A.; Ma, C.C.; Tang, H.J.; Yen, T.C.; Wei, K.C. The Effectiveness of a Magnetic 
Nanoparticle-Based Delivery System for BCNU in the Treatment of Gliomas. 
Biomaterials, 2011, 32, 516–527. 
49. Liu, Y.C.; Ny, A.L.M.L.; Schmidt, J.; Talmon, Y.; Chmelka, B.F.; Lee, C.T. Photo-
Assisted Gene Delivery Using Light-Responsive Catanionic Vesicles. Langmuir, 2009, 
25, 5713–5724. 
50. Liu, J.; Choi, E.; Tamanoi, F.; Zink, J.I. Light-Activated Nanoimpeller-Controlled Drug 
Release in Cancer Cells. Small, 2008, 4, 421–426. 
		
	
19 
51. Deng, Z.; Zhen, Z.; Hu, X.; Wu, S.; Xu, Z.; Chu, P.K. Hollow Chitosan-Silica 
Nanospheres as pH-Sensitive Targeted Delivery Carriers in Breast Cancer Therapy. 
Biomaterials, 2011, 32, 4976–4986. 
52. Gao, G.H.; Park, M.J.; Li, Y.; Im, G.H.; Kim, J.H.; Kim, H.N.; Lee, J.W.; Jeon, P.; Bang, 
O.Y.; Lee, J.H.; Lee, D.S. The Use of pH-Sensitive Positively Charged Polymeric 
Micelles for Protein Delivery. Biomaterials, 2012, 33, 9157–9164. 
53. Sun, Y.; Yan, X.; Yuan, T.; Liang, J.; Fan, Y.; Gu, Z.; Zhang, X. Disassemblable Micelles 
Based on Reduction-Degradable Amphiphilic Graft Copolymers for Intracellular Delivery 
of Doxorubicin. Biomaterials, 2010, 31, 7124–7131. 
54. Li, J.; Huo, M.; Wang, J.; Zhou, J.; Mohammad, J.M.; Zhang, Y.; Zhu, Q.; Waddad, A.Y.; 
Zhang, Q. Redox-Sensitive Micelles Self-Assembled from Amphiphilic Hyaluronic Acid-
Deoxycholic Acid Conjugates for Targeted Intracellular Delivery of Paclitaxel. 
Biomaterials, 2012, 33, 2310–2320. 
55. Wang, Y.C.; Wang, F.; Sun, T.M.; Wang, J. Redox-Responsive Nanoparticles from the 
Single Disulfide Bond-Bridged Block Copolymer as Drug Carriers for Overcoming 
Multidrug Resistance in Cancer Cells. Bioconjug. Chem., 2011, 22, 1939–1945. 
56. Zhu, L.; Kate, P.; Torchilin, V.P. Matrix Metalloprotease 2-Responsive Multifunctional 
Liposomal Nanocarrier for Enhanced Tumor Targeting. ACS Nano, 2012, 6, 3491–3498. 
57. Hatakeyama, H.; Akita, H.; Ito, E.; Hayashi, Y.; Oishi, M.; Nagasaki, Y.; Danev, R.; 
Nagayama, K.; Kaji, N.; Kikuchi, H.; Baba, Y.; Harashima, H. Systemic Delivery of 
siRNA to Tumors Using a Lipid Nanoparticle Containing a Tumor-Specific Cleavable 
PEG-Lipid. Biomaterials, 2011, 32, 4306–4316. 
58. Shen, S.; Wu, Y.; Liu, Y.; Wu, D. High Drug-Loading Nanomedicines: Progress, Current 
		
	
20 
Status, and Prospects. Int. J. Nanomedicine, 2017, 12, 4085–4109. 
59. Bhushan, B.; Khanadeev, V.; Khlebtsov, B.; Khlebtsov, N.; Gopinath, P. Impact of 
Albumin Based Approaches in Nanomedicine: Imaging, Targeting and Drug Delivery. 
Adv. Colloid Interface Sci., 2017, 246, 13–39. 
60. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cnacer 
Chemotherapy: Mechanism of Tumoritropic Accumulatio of Proteins and the Antitumor 
Agents Smancs. Cancer Res., 1986, 46, 6387–6392. 
61. Davis, M.E.; Chen, Z.; Shin, D.M. Nanoparticle Therapeutics: An Emerging Treatment 
Modality for Cancer. Nat. Rev. Drug Discov., 2008, 7, 771–782. 
62. Byrne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active Targeting Schemes for 
Nanoparticle Systems in Cancer Therapeutics. Adv. Drug Deliv. Rev., 2008, 60, 1615–
1626. 
63. Marin, E.; Briceño, M.I.; Caballero-George, C. Critical Evaluation of Biodegradable 
Polymers Used in Nanodrugs. Int. J. Nanomedicine, 2013, 8, 3071–3091. 
64. Nishida, H.; Tokiwa, Y. Effects of Higher-Order Structure of Poly(3-Hydrolxybutyrate) 
on Biodegradation. Ll Effects of Crystal Structure on Microbial Degradation. J. Environ. 
Polym. Degrad., 1993, 1, 65–80. 
65. Friess, W. Collagen - Biomaterial for Drug Delivery. Eur. J. Pharm. Biopharm., 1998, 45, 
113–136. 
66. Lutolf, M.P.; Hubbell, J.A. Synthetic Biomaterials as Instructive Extracellular 
Microenvironments for Morphogenesis in Tissue Engineering. Nat. Biotechnol., 2005, 23, 
47–55. 
67. Pillai, O.; Panchagnula, R. Polymers in Drug Delivery Omathanu Pillai and Ramesh 
		
	
21 
Panchagnula. Curr. Opin. Chem. Biol., 2001, 5, 447–451. 
68. Patel, H.M. Serum Opsonins and Liposomes: Their Interaction and Opsonophagocytosis. 
Crit. Rev. Ther. Drug Carrier Syst., 1992, 9, 39–90. 
69. Price, M.E.; Cornelius, R.M.; Brash, J.L. Protein Adsorption to Polyethylene Glycol 
Modified Liposomes from Fibrinogen Solution and from Plasma. Biochim. Biophys. Acta - 
Biomembr., 2001, 1512, 191–205. 
70. Papahadjopoulos, D.; Allen, T.M.; Gabizon, A.; Mayhew, E.; Matthay, K.; Huang, S.K.; 
Lee, K.D.; Woodle, M.C.; Lasic, D.D.; Redemann, C. Sterically Stabilized Liposomes: 
Improvements in Pharmacokinetics and Antitumor Therapeutic Efficacy. Proc. Natl. 
Acad. Sci. U. S. A., 1991, 88, 11460–11464. 
71. Merdan, T.; Kopec̆ek, J.; Kissel, T. Prospects for Cationic Polymers in Gene and 
Oligonucleotide Therapy against Cancer. Adv. Drug Deliv. Rev., 2002, 54, 715–758. 
72. Bartlett, D.W.; Davis, M.E. Physicochemical and Biological Characterization of Targeted, 
Nucleic Acid-Containing Nanoparticles. Bioconjug. Chem., 2007, 18, 456–468. 
73. Gene Therapy Clinical Trials Worldwide. http://www.abedia.com/wiley/vectors.php 
(Accessed Jan 18, 2018). 
74. Robbins, P.D.; Ghivizzani, S.C. Viral Vectors for Gene Therapy. Pharmacol. Ther., 1998, 
80, 35–47. 
75. Thomas, C.E.; Ehrhardt, A.; Kay, M.A. Progress and Problems with the Use of Viral 
Vectors for Gene Therapy. Nat. Rev. Genet., 2003, 4, 346–358. 
 
 
 
		
	
22 
CHAPTER 2 
POLYAMIDE NANOGELS BASED ON GRAS COMPONENTS AS BIOCOMPATIBLE 
NANOCARRIERS 
 
 Adapted with permission from Prasad, P.; Molla, M. R.; Cui, W.; Canakci, M.; Osborne, 
B.; Mager, J.; Thayumanavan, S. Polyamide Nanogels from Generally Recognized as Safe 
Components and Their Toxicity in Mouse Preimplantation Embryos. Biomacromolecules, 2015, 
16, 3491– 3498. Copyright © 2015 American Chemical Society. 
2.1 Introduction 
The need for the development of drug delivery systems is rather broad, although significant 
attention has been paid to cancer therapy because of the severity and often fatal nature of the 
disease.1 With better understanding of the tumor biology, nanocarriers have emerged as a superior 
class of drug delivery system as they can exploit the leaky vasculature of tumor tissues for selective 
uptake.2-11 Amongst the nanocarriers that are being developed for this purpose, polymeric micelles 
have attracted particular attention as these nanoassemblies can noncovalently encapsulate the 
hydrophobic drug molecules in aqueous conditions.12-23  Although polymer micelles show great 
promise in many cases, these assemblies face a general conundrum with respect to drug loading 
and encapsulation stability.  For high encapsulation stability, it is necessary that the hydrophobic 
part of the micellar assembly is glassy so as to keep the guest molecules from leaking into the bulk.  
On the other hand, if the interior of the assembly is glassy, loading the drug molecules become an 
issue.  The successful utility of polymer micelles however in the drug delivery area has 
demonstrated that ‘sweet spots’ can indeed be identified to develop useful nanocarriers.  A 
complementary approach that can offer a viable solution to this issue involves chemically 
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crosslinked polymeric assemblies, where the loading can occur when the assemblies are rather lose 
and the encapsulation stability is achieved due to the crosslinking-induced incarceration of the 
drug molecules.24-28 Such a crosslinking strategy also offers the opportunity to programming the 
assemblies to uncrosslink and release its contents only in the presence of a specific stimulus.29-38 
Above all, safety of the drug carriers is of utmost importance and therefore it is critical that 
a carrier is biocompatible.39 A promising approach to develop biocompatible scaffolds is to design 
the components of the assembly such that they are biodegradable and that the degradation products 
are non-toxic.40-47 In this manuscript, we introduce the design of a stimuli responsive polymeric 
nanogel system, which can stably encapsulate hydrophobic guest molecules.  The polymer is 
designed such that the degraded product of the polymeric nanogel would be composed of 
molecules that are generally accepted to be biocompatible.  GRAS is the acronym used by the U. 
S. Food and Drug Administration (FDA) for molecules that are generally regarded as safe, which 
provides an idea of molecules that are suitable as additives in food products or for use in medical 
devices.48   
 Our target was to synthesize a crosslinked polymeric nanogel, which contains disulfide 
crosslinks using GRAS components.  We started with the reasonable assumption that degradation 
of the polymeric nanogel, under biological conditions, will occur through hydrolysis of esters and 
amides in addition to the reductive cleavage of the disulfide bonds.44 We chose glutamic acid (a 
naturally occurring amino acid) and putrescine (one of the growth factors for cell division) as 
components of a degradable polyamide backbone. The dicarboxylic acid nature of the glutamic 
acid and the diamino nature of putrescine will be used to synthesize the amide-based polymer 
backbone.  The amino moiety in the glutamic acid will then be used as the handle to introduce 
functional groups that cause self-assembly of this polymer into a nanogel, as well as to incorporate 
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surface functional groups, and the crosslinkable functional groups.  The polyamide, from glutamic 
acid and putrescine, is functionalized with the hydrophilic oligoethyleneglycol (OEG) moiety and 
the hydrophobic pyridyl disulfide (PDS) moiety.  Since this functionalization will render the 
polymer amphiphilic, this is prone to self-assemble which can then be converted to a crosslinked 
polymer nanogel using the recently introduced self-crosslinking strategy using the PDS unit as the 
handle.24 Similarly, in addition to providing the hydrophilic component, the OEG moiety also has 
the potential to endow the nanogel with a surface functionality that is known to endow nanocarriers  
with reduced non-specific interactions in serum.9 Note that the degradation of the side chain 
functional groups in the nanogel will provide oligoethyleneglycol carboxylic acid and 
thiopropionic acid, both of which are also considered to be biocompatible and safe.  Structures of 
the targeted polymer and the nanogel are shown in Scheme 2.1.  
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2.2 Results and Discussion  
2.2.1 Design and Synthesis  
The precursor polymer was achieved by first synthesizing the polymer backbone with 
amino moieties of glutamic acid available for post-polymer functionalization.  Synthesis of this 
polymer started with the reaction between the bis-N-hydroxysuccinimide ester of N-Boc-L-
Scheme 2. 1 Top: Schematic representation of hydrophobic guest encapsulation, 
followed by redox responsive release and degradation by enzymes; Bottom: 
Chemical structure of the nanogel precursor polymer. 
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glutamic acid (1) and putrescine (2) (Scheme 2.1).  The resultant copolymer, which was 
characterized by 1H NMR and gel permeation chromatography (GPC), was found to have an Mn 
of 8.3 kDa. Removal of the N-boc- moiety from the polymer was achieved using trifluoro acetic 
acid, the conversion of which was quantitative as discerned by 1H NMR.  The amine in polymer 
P1 was then treated with excess but equal amounts of the N-hydroxysuccinimide esters of 
olgioethyleneglycol monocarboxylic acid and PDS-protected thiopropionic acid, as shown in 
Scheme 2.2.  After removing the excess reagents through dialysis, the final conjugation ratio in 
the target polymer P2 was determined by 1H NMR by the characteristic peaks of the PDS moiety 
at 8.5 ppm and that of the PEG methoxy group at 3.35 ppm (Refer to experiment protocol section).  
The ratio of these moieties was found to be 7:3 for the hydrophilic and hydrophobic side chains. 
The difference in the conjugation ratio is possibly due to the difference in reactivity of the two side 
chains.  
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2.2.2 Self Assembly Characterization 
Since the polymer is amphiphilic in nature, it is expected to self-assemble in aqueous 
solution. This possibility was evaluated using dynamic light scattering (DLS) and hydrophobic 
dye encapsulation studies in solution, complemented by transmission electron microscopy (TEM) 
(Figure 2.1). DLS experiments were carried out with a 1 mg/mL solution of polymer P2 in water 
and the aggregates were ~90 nm.  Size estimates from TEM also support the DLS measurement.  
The TEM data also revealed that the assembly has a spherical morphology; the slight departure 
from a perfectly spherical shape is attributed to the soft nature of the polymer assembly and the 
nanogel.  Although TEM is the dried version of the solution phase assembly, measured in the DLS, 
Scheme 2. 2 Synthetic scheme for the nanogel precursor polymer and nanogel. 
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since the sizes from these two measurements correlate, it is a reasonable assumption that the 
morphology of the aggregates is indeed spherical in solution.  Next, we wanted to test if these 
amphiphilic polymeric aggregates are capable of encapsulating hydrophobic molecules in an 
aqueous medium. To test this, we used a hydrophobic dye 1,1-dioctadecyl-3,3,3, -
tetramethylindocarbocyanine perchlorate (DiI) as a fluorescent probe. The dye in itself does not 
show any absorption in water, as it is not soluble.  However, when dissolved in the presence of the 
polymeric aggregates, its apparent solubility is evident by absorption spectrum (Figure 2.1). 
 
 
 
2.2.3 Nanogel Formation and Characterization 
Next, we were interested in trapping these nanoscale aggregates through chemical 
crosslinking.  We utilized the self-crosslinking strategy in which a sub-stoichiometric amount of 
dithiothreitol (DTT) is added to the solution containing these aggregates.  Briefly, DTT executes 
a rapid cleavage of the disulfide units from the PDS moieties.  Since the pyridothione byproduct 
is stable and unreactive, the thiol moieties generated in the polymer chain now undergo a thiol-
disulfide exchange with the remaining PDS units within the aggregate to cause crosslinked 
polymeric nanogels.  The key question here is whether this crosslinking reaction is intra-aggregate 
Figure 2. 1 Self-assembly of polymeric aggregates as seen by a) dynamic light scattering, b) 
transmission electron microscopy (scale 500nm) and c) hydrophobic guest encapsulation. 
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or inter-aggregate.  If this is intra-aggregate, then the size of the crosslinked nanogel should closely 
correlate with the amphiphilic aggregate from P2.  Indeed, we found the size of the crosslinked 
nanogel to be very similar to that of the aggregate (see Figure 2.2).  In generating the nanogels, it 
is also possible to control the crosslink densities by simply varying the amount of DTT added to 
the reaction mixture (see SI).  To see whether the extent of crosslinking correlates with the amount 
of DTT added, we monitored the amount of pyridothione generated in the reaction.  We found this 
to closely correlate with each other, which suggest that the DTT-induced cleavage of the PDS units 
and the subsequent crosslinking reactions are nearly quantitative.  We prepared two nanogels, NG1 
and NG2 with 3% and 5% cross-linking densities respectively.  NG2 was used for all the 
subsequent studies outlined below.  
2.2.4 Redox Responsive Release 
Once a molecule is encapsulated within the interior, it is also critical that we are able to 
trigger the release of these molecules in response to a specific stimulus.  Since our nanogels consist 
of disulfide crosslinks, they should be responsive to thiol-based reducing environments. 
Figure 2. 2 a) Absorption spectra of pyridothione in UV-vis. Pyridothione, which is a byproduct 
during nanogel synthesis by disulfide bond formation and shows characteristic absorption at 343 
nm wavelength; b) Size distribution of nanogels in water; c) TEM images of nanogels (scale 
500nm). 
 
		
	
30 
Glutathione (GSH) is a reducing agent found in millimolar concentrations in the cytosol, while its 
concentration in the extracellular environment is micromolar.  Thus, we tested the release of the 
encapsulated dye molecule from the NG2 nanogel scaffold in the presence of 10 mM GSH.  We 
observed that in the presence of GSH, the guest molecule was released from the nanogel as 
discerned from the decrease in the absorption spectrum.  The decrease in absorbance of DiI is 
attributed to the precipitation of the rather hydrophobic guest molecule in water, upon release from 
the nanogel due to the GSH-triggered decrosslinking (Figure 2.3). In a control experiment, where 
no GSH was added to the solution, the decrease in absorbance was much slower which indicates 
that the guest molecule release is indeed occurring due to the decrosslinking of the nanogel scaffold 
in the presence of GSH.  
2.2.5 Toxicity Assessment 
The key motivation behind designing a polymer with GRAS components is to design a 
polymeric nanogel, which exhibit very low toxicity.  Accordingly, we first tested the in vitro 
cellular viability of our nanogels on HEK-293T and HeLa cell lines using the Alamar blue assay. 
NG2 which was incubated along with cell lines for 24 hours at 37 °C showed high and 
concentration independent cellular viability for up to a concentration of 0.5 mg/mL (Figure 2.4). 
Figure 2. 3 DiI release from nanogels in response to 10 mM GSH over time. 
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Cytotoxicity studies are meaningful, only when the nanoassembly gains access to the cells and still 
prove not to be cytotoxic.  Therefore, we also tested whether these nanogels can undergo cellular 
internalization.  We performed in vitro cellular uptake of nanogels encapsulated with hydrophobic 
dye, 3,3'-dioctadecyloxa-carbocyanine perchlorate (DiO), where the nanogels were incubated with 
HeLa cells for 12 hours and evaluated by confocal microscopy.  It was noted that nanogels enter 
the cells within this time period and that these are distributed throughout the cytoplasm, as shown 
in Figure 2.4.   It is also possible that the guest molecules can leak from the nanogels, where the 
hydrophobic dyes can passively diffuse into the cells.  If DiO escaped the nanogel, it would mainly 
bind to the cell membrane rather than diffuse into the cytosol. To confirm that the DiO signal 
observed was not due to escape from nanogels, we covalently attached fluorescein to the nanogels 
and examined them for cellular uptake. The fluorescein-labeled nanogels were similarly incubated 
with HeLa cells for 12 hours at 37 °C and examined by confocal microscopy.  It is again clear that 
the nanogels were not only taken up by the cells, but also that these nanogels are uniformly 
distributed throughout the cytosol (Figure 2.4). 
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Figure 2. 4 Top: In vitro cell viability of nanogels on 293T and HeLa cell line after 24 hour of 
incubation, confocal microscopy images of HeLa cells after incubation for 12 hrs with Middle: 
DiO loaded nanogels (left: DiO channel, middle: DIC image, right: overlap of both) and Bottom: 
FITC conjugated nanogels (left to right: DAPI channel, FITC channel, overlap of both channels, 
DIC image with overlap); Scale (20 µm) 
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We further evaluated the toxicity of the nanogels using a more rigorous test.  We cultured 
mouse preimplantation embryos in the presence of nanogels.  Preimplantation embryos are 
generally more sensitive to toxicants than regular somatic cells49-50 and must undergo several 
morphogenetic events in order to successfully develop into a blastocyst over a 4-day period. 
Perturbations in many cellular events, defective cell cycle and cell lethality are known to disrupt 
blastocyst development.51 Therefore, assessing the development of embryos in the presence of 
nanogels is a highly sensitive method for evaluating toxicity.  We carefully monitored 
development of embryos in culture - with and without nanogels.  We were gratified to find no 
differences in development rate or efficiency of blastocyst formation in the presence of nanogels. 
Both the control group (KSOM, negative control) and KSOM supplemented with fluorescein-
labeled nanogels (nanogel-FITC) developed blastocysts after 4 days in culture (Figure 2.5 A-B). 
In addition, fluorescence signal was also detected in nanogel-FITC blastocysts, but not in the 
negative controls (Figure 2.5 A-B) indicating that the nanogel-FITC was taken up by blastomeres 
during preimplantation development, but did not exhibit any disruption to developmental potential 
of embryos. These results show that the nanogels are highly biocompatible and non-toxic to 
mammalian preimplantation embryos and pluripotent cells.    
To further investigate toxicity, early blastocysts were transferred into pseudo-pregnant 
recipients in order to determine pups can be born after 3 days of preimplantation nanogel exposure.  
Live pups were born at equivalent rates to controls after preimplantation development in the 
presence of glutamic acid nanogels (Figure 2.5D).  Taken together, our results indicate that the 
glutamic acid nanogels are biocompatible and non-toxic to mammalian preimplantation 
development which is quite sensitive to the culture environment52 and that fetal development after 
culture in the nanogels is similarly unaffected permitting normal growth and survival to birth. 
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2.3 Summary 
In summary, we have developed a new polyamide nanogel, the building blocks of which 
are based on biocompatible components.  The backbone of the polyamide is based on glutamic 
acid and putrescine, while the side chain substituents are based on oligoethyleneglycol and 
thiopropionic acid.  Since the precursor to these side chain substituents make the polyamide 
amphiphilic, the polymer self-assembles in aqueous solutions. Disulfide crosslinked polymeric 
nanogels have been obtained using this self-assembly, while concurrently taking advantage of the 
amphiphilic nature of the assembly to sequester hydrophobic molecules within its interior. Since 
the crosslinks are based on disulfide functionalities, these nanogels exhibit molecular release in 
response to the intracellular stimulus, glutathione.  Finally, to test the versatility of the 
biocompatible nanogel design, these nanogels were tested for toxicity using a more classical 
cytotoxicity assay and a more rigorous and highly sensitive mammalian preimplantation 
Figure 2. 5 Mouse blastocyst formation and embryo transfer results. Blastocysts were formed 
after 4 days of in vitro culture with (A, A’) or without (B, B’) FITC-nanogels. For in vivo 
experiment, early embryos were firstly cultured for 3 days in vitro with (C, C’) or without (D) 
FITC-nanogels, then these morulae/early blastocysts were transferred to the uteri of recipients. E, 
live pups born with nanogel exposure during preimplantation development. 
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development assay.  In both assays, the nanogels exhibit no discernible toxicity, suggesting that 
these GRAS-based stimuli responsive nanogels has great potential for in vivo applications.  
2.4 Experimental Details 
2.4.1 Materials and Methods 
All the reagents were purchased from commercial source and used as such without further 
purification. 1H NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer using the 
residual proton resonance of the solvent as the internal standard. Chemical shifts (δ) are reported 
in parts per million (ppm) and Hertz, respectively. The following abbreviations are used for the 
peak multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublet; 
bs, broad singlet; bd, broad doublet; bm, broad multiplet. Molecular weight of the polymers was 
estimated by gel permeation chromatography (GPC) using PMMA standard with a refractive index 
detector. Dynamic Light Scattering (DLS) measurements were carried out on a Malvern 
Nanozetasizer. TEM images were recorded on a JEOL-2000FX machine operating at an 
accelerating voltage of 100 kV. Cell imaging was performed using a Zeiss 510 META confocal 
microscope. Fluorescence measurements were performed on a fluorescence plate reader 
(Molecular Devices, SpectraMax M5). 
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2.4.2 Synthesis Procedures and Characterization of Molecules  
 
Scheme 2. 3 Synthesis Procedures and Characterization of Molecules. 
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Synthesis of compound 1: 
                                                                            
500 mg (4.04 mmol) of Boc-l-glutamic acid and 574.7 mg (9.99 mmol) of N-
Hydroxysuccinimide were added in a round bottom flask and dissolved in DMF followed by the 
addition of 775 mg (10 mmol) of EDC.HCl. The reaction mixture was stirred overnight under 
Argon atmosphere at RT. After concentration under vacuum, water was added and the product was 
extracted with ethyl acetate (X3). The combined organic phase was washed with 0.1 N HCl (X2), 
brine, saturated NaHCO3 (X2) and dried over MgSO4. Concentration under reduced pressure 
afforded the corresponding di-activated ester. The product was obtained as a white solid powder 
in 40% yield. 
1H-NMR (400 MHz, (CD3)2CO, TMS): δ (ppm) = 6.8 (m, 1H), 4.7 (m, 1H), 2.9 (m, 2H), 2.8 (s, 
8H), 2.4 (m, 1H), 2.3 (m, 1H) 1.37 (s, 9H). 
Synthesis of polymer 2:  
                                               
100 mg (0.226 mmol) of N-boc-L-glutamic acid di activated ester was added in a round 
bottom flask with DMF for stirring. 52.47 µL (0.376 mmol) of triethyl amine was then added to 
the solution followed by adding 22.7 µL (0.226 mmol) of 1, 4 diaminobutane. The reaction was 
stirred overnight and quenched by cooling it. The final product was purified by precipitating it in 
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diethyl ether followed by dialysis using a cut off membrane of Mn 3.5 kDa in methanol. The 
product is isolated as an off-white sticky solid.  
1H-NMR (400 MHz, CD3OD, TMS): δ (ppm) = 3.98 (s, 1H), 3.17 (m, 4H), 2.25 (m, 2H), 2.01 (m, 
1H), 1.85 (m, 1H), 1.47 (s, 4H), 1.46 (s, 9H) 
Synthesis of polymer 3:   
                                                
 In a typical procedure, polymer 2 is taken in a round bottom flask followed by the addition 
of TFA/DCM mixture. TFA is taken in 5 times excess. The reaction mixture is left for stirring for 
4 hours. Excess solvent and TFA is removed by evaporation under reduced pressure.     
1H-NMR (400 MHz, CD3OD, TMS): δ (ppm) = 3.88(m, 1H), 3.19 (m, 4H), 2.37 (m, 2H), 2.09 (m, 
2H), 1.55(s, 4H).      
Synthesis of compound 4:  
                                                         
1.87 gm (8.5 mmol) of Aldrithiol was added in a round bottom flask with ethanol and kept 
for stirring in an ice bath. Acetic acid was added in catalytic amount. 0.45 gm (4.25 mmol) 
mercapto propionic acid dissolved in ethanol was then added to the reaction mixture drop wise. 
The reaction was stirred overnight. The product was concentrated under vacuum and purified by 
column chromatography using silica gel as stationary phase and hexane/Ethyl acetate as eluent. 
Finally, pure product was separated as light yellow solid in 80 % yield. 
1H-NMR (400 MHz, CDCl3, TMS): δ (ppm) = 8.48 (m, 1H), 7.65 (m, 2H), 7.14 (m, 1H), 3.07 (t, 
2H), 2.79 (t, 2H). 
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Synthesis of compound 5: 
                                                   
 620 mg (2.88 mmol) of PDS acid obtained from previous step and 365 mg (3.17 mmol) of 
N-hydroxysuccinimide were dissolved in dichloromethane (DCM) in a round bottom flask and 
cooled in an ice bath to 0oC.  492 mg (155.24 mmol) of EDC.HCl in DCM was then added to the 
reaction mixture. This was stirred overnight. The product was concentrated in vacuum and 
redissolved in ethyl acetate and extracted with water, NaHCO3 and brine followed by drying it 
over MgSO4. The product was concentrated under vacuum and purified by flash chromatography 
using silica gel as stationary phase and hexane/Ethyl acetate as eluent. Finally, pure product was 
separated as light yellow solid in 37 % yield. 
1H-NMR (400 MHz, CDCl3, TMS): δ (ppm) = 8.48 (m, 1H), 7.65 (m, 2H), 7.14 (m, 1H), 3.12 (m, 
4H), 2.84 (s, 4H). 
 
Synthesis of compound 6: 
                                                             
A reported procedure was followed for the synthesis 53 
1H-NMR (400 MHz, CDCl3, TMS): δ (ppm) = 4.15 (s, 2H), 3.55-3.76 (m, 24H), 3.37 (s, 3H) 
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Synthesis of compound 7: 
                                                        
 A reported procedure was followed for the synthesis 53 
1H-NMR (400 MHz, CDCl3, TMS): δ (ppm) = 4.5 (s, 2H), 3.55-3.76 (m, 24H), 3.37 (s, 3H), 2.84 
(s, 4H) 
Synthesis of polymer 8: 
                 
75 mg (0.3483 mmol) of polymer (3) and 97l (0.6966 mmol) of triethyl amine was dissolved in 
DMF in a round bottom flask. 113 mg (0.2786 mmol) of PEG-NHS and 87 mg (0.2786 mmol) of 
PDS-NHS was then added to the reaction mixture and stirred overnight. The product was then 
dialysed in methanol with a 3.5 KDa cutoff membrane. 
1H-NMR (400 MHz, CD3OD, TMS): δ (ppm) = 8.4 (m,1H), 8 (m,1H ), 7.93 (m, 2H), 7.58 (m, 
2H), 7.3 (m,1H ), 7.28(m, 1H), 4.38 (m, 2H ), 4.04  (m, 2H), 3.6-3.7 (m, 25H ), 3.52-3.54 (m, 2H), 
3.35 (s, 3H), 3.12-3.21 (m, 8H), 2.26 (m, 4H ), 2.08 (m, 2H ), 1.93 (m, 2H ), 1.51 (s, 8H ). The 
O O
O
N
O
O
O
7
H
N N
H
N
H
H
N
O
HN O
O
O
O
NHO
SS
O
O
x y
7
N
		
	
41 
molar ratio between two blocks was determined by integrating the methoxy proton in the 
polyethylene glycol unit (3.3 ppm) and the aromatic proton in the pyridine (8.4 ppm). 
2.4.3 Other Experimental Protocols 
2.4.3.1 Dynamic Light Scattering (DLS) Study 
 DLS was performed on a Malvern Nano-zeta sizer instrument with a 637 nm laser source 
with non-invasive backscattering technology detected at 173⁰. All sizes are reported as the 
hydrodynamic diameter (DH) and were repeated in triplicate. For the DLS measurements, the 
concentration of the polymer and nanogel solution was 1 mg/mL. The solution was filtered using 
a hydrophilic membrane (pore size 0.450 µm) before experiment was performed.    
2.4.3.2 Transmission Electron Microscope (TEM) Study 
For the TEM measurements the nanogel solution was prepared in 1 mg/mL concentration. 
One drop of the sample (10 µL) was dropcasted on carbon coated Cu grid, 400 mesh size and left 
to dry overnight.  
2.4.3.3 In vitro Cell Viability 
The in vitro cellular viability of the nanogels was evaluated on healthy 293T and HeLa 
cancer cell lines. The cells were cultured in T75 cell culture flasks using Dulbecco's Modified 
Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) with 10 % fetal bovine serum (FBS) 
supplement. The cells were seeded at 10,000 cells/well/200 µL in a 96 well plate and allowed to 
grow for 24 hours under incubation at 37 °C and 5 % CO2. These cells were then treated with 
nanogels of different concentrations and were incubated for another 24 hours. Cell viability was 
measured using the Alamar Blue assay with each data point measured in triplicate. Fluorescence 
measurements were made using the plate reader SpectraMax M5 by setting the excitation 
wavelength at 560 nm and monitoring emission at 590 nm on a black well plate. 
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2.4.3.4 In vitro cell uptake 
FITC labeled nanogels was synthesized using the amines in the polymer for conjugation 
with FITC. In a vial, polymer was dissolved in methanol and excess FITC was added. The solution 
was let to stir overnight followed by extensive dialysis in methanol using cut off membrane Mn- 
3500 Da. Nanogel was prepared using the same procedure as described previously. 
In a glass bottom dish, HeLa cells were incubated overnight at 37°C and 5 % CO2 with 
nutrient medium (DMEM/F12 with 10% fetal bovine serum supplement). The nutrient medium 
was then taken out and the cells were washed with pH 7.4 PBS buffer. To it 100 µL of the nanogel 
solution (10 mg/mL) either encapsulated with DiO or conjugated with FITC were added along 
with the nutrient medium. The cells were then incubated for 30 min at 37 0C and the fluorescence 
was observed under a confocal microscope (63X oil immersion objective)  
2.4.3.5 Embryo Recovery and Culture 
B6D2F1 female mice (8 to 10 weeks old) were induced to superovulate with 5 IU pregnant 
mare's serum gonadotropin (PMSG, Sigma), followed 46-48 h later by 5 IU human chorionic 
gonadotropin (hCG, Sigma). Females were mated with B6D2F1 males immediately after hCG 
injection, and euthanized at 20-22 h post-hCG injection. Oviductal ampullae were cut open to 
release zygotes, and cumulus cells were removed by pipetting in M2 medium (Millipore) 
containing 0.1% hyaluronidase (Sigma). Zygotes were cultured in KSOM medium (Millipore) or 
KSOM supplemented with 1 mg/mL of nanogel solution at 37 °C, 5% CO2/5% O2 balanced in N2 
for 4 days. Use of vertebrate animals for embryo production was approved by the University of 
Massachusetts IACUC. 
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2.4.3.6 Embryo Transfer 
Morulae/early blastocysts after 3 days of culture in KSOM or KSOM supplemented with 
nanogels were transferred into uteri of 2.5 dpc (day post coitus) pseudopregnant foster dams (CD-
1 mice, albino) by using the non-surgical embryo transfer (NSET) device. Recipient females were 
allowed to deliver pups naturally in order to observe production of live healthy animals after 
preimplantation development in the presence of nanogel   solution. 
2.4.3.7 Procedure for dye encapsulation 
The polymer 8 (1 mg/mL) was dissolved in water. 10 µL (0.01 mg) of DiI (1mg/mL in 
acetone) was added to the stirring solution of polymer followed by the desired amount of DTT for 
crosslinking. The mixture was stirred overnight at room temperature, open to the atmosphere 
allowing the organic solvent to evaporate. Excess insoluble DiI was removed by filtration and 
pyridothione was removed from the nanogel solution by dialysis using a membrane with molecular 
cut-off of 3.5 kDa. 
2.4.3.8 Procedure for nanogel formation 
Followed a reported procedure 54 
In order to determine the crosslinking density, UV-vis measurements were performed with samples 
of the solution reacted with DTT. Once this was measured, we calculated the amount of 
pyridothione based on its known molar extinction coefficient (8.08 x 103 M-1 cm-1 at 343 nm).  
The percentage of cross-linking was calculated by assuming that formation of a single, 
crosslinking disulfide bond would require cleavage of two PDS units and produce two 
pyridothione molecules.                     
Calculation of crosslinking density:  
• Sample concentration in UV: 0.5 mg/ml of polymer.  
		
	
44 
•  The molar ratio of each unit: PDS:PEG= x mol : y mol=30:70 (from 1H-NMR)  
•  PDS molecular weight = 430 g/mol, PEG molecular weight = 475 g/mol  
So, x mol * 430 g/mol + y mol * 275 g/mol= 0.5mg x mol = 30/70 y mol  
Therefore, x mole (PDS) is 2.8 * 10-7 mol in this solution  
NG1 Absorbance is 0.125 at 343 nm.  
By Beer’s law, A=εbc  
0.125=8.08*103 M-1 cm-1 * 1 cm * c 
c = 1.5 * 10-5 M  
Therefore, 1ml of resulting nanogel solution contains 1.5 *10-8 mol pyridothione (byproduct). It is 
5.3 mol% of total PDS unit (2.8*10-7 mol). We assume two pyridothiones are from one disulfide 
formation and PDS unit is 30 mol% of total polymer. Therefore, 5.3 % /2 *0.3 = 0.8 % crosslinking 
density.      
NG2 Absorbance is 0.23 at 343 nm.  
By Beer’s law, A = εbc  
0.23= 8.08*103 M-1 cm-1 * 1 cm * c 
c = 2.8 * 10-5 M  
Therefore, 1ml of resulting nanogel solution contains 2.8*10-8 mol pyridothione (byproduct). It is 
10 mol% of total PDS unit (2.8*10-7 mol). We assume that two pyridothione are from one disulfide 
formation and PDS unit is 30 mol% of total polymer. Therefore, 10 % /2 *0.3 = 1.5 % crosslinking 
density.  
2.4.3.9 Degradation of nanogel in serum 
 1.2 mg of nanogel was incubated in 1.5 mL of fetal bovine serum at 37 °C, 10% CO2. 
Before testing the molecular weight by gel permeation chromatography (GPC), 150 µL of the 
		
	
45 
solution was precipitated in 1.5 mL of cold methanol and the serum proteins were separated by 
centrifugation. 1.6 mL of the supernatant was then separated and evaporated before analyzing by 
GPC. 
 
 
 
 
 
 
 
 
 
 
Figure 2. 6 Nanogel degradation in serum over a period of 6 days as seen by GPC chromatogram 
in DMF by the gradual increase in elution time indicating decrease in molecular weight. 
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2.4.4 1H- NMR 
*: solvent residues are marked with stars. 
 
 
 
 
 
 
 
Figure 2. 7 1H-NMR spectrum of molecule 4. 
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Figure 2. 8 1H-NMR spectrum of molecule 5. 
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Figure 2. 9 1H-NMR spectrum of molecule 6. 
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Figure 2. 10 1H-NMR spectrum of molecule 7. 
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Figure 2. 11 1H-NMR spectrum of Polymer 3. 
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Figure 2. 12 1H-NMR spectrum of polymer 8. 
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CHAPTER 3 
EVALUATION OF METHODS TO QUANTIFY DRUG LOADING IN CROSSLINKED 
BLOCK CO-POLYMER NANOGELS 
3.1 Introduction 
 Research in developing nanocarriers for cancer therapeutics has significantly progressed 
over the last two decades. We now understand many factors that are essential and required in 
developing and designing better nanocarriers for drug delivery. Among the most vital properties 
of a drug delivery carrier are targeting, retaining and releasing.76 Amphiphilic block copolymers 
self-assemble into micellar aggregates in aqueous solutions and are typically in the lower 
nanometer size range.77–79 Macromolecules of this size can exploit the leaky vasculature of solid 
tumors for passive targeting. This effect is well studied and known as enhanced permeation and 
retention effect where nanoparticles can accumulate in the fenestrations of vascular epithelium 
which is caused by extensive angiogenesis.80–83 Advantages of designing nanoparticles with high 
drug loading are manifold. For nanoparticles that are administered intravenously, less than one 
tenth of the administered particles are retained in systemic circulation after 12 hours.84 Also, since 
most nanocarriers have poor drug loading, typically higher doses and/ or increased frequency of 
administration are required to achieve a clinically relevant dose. This can cause side effects from 
using excess amounts of nanocarriers and is additionally not suited for patient care.  Block 
copolymers with a glassy hydrophobic core are known to have high drug loading.85–88 It is 
imperative that once the nanocarriers reaches the target, there is a stimulus for drug release. There 
are exogenous stimuli – temperature,44–46 light,49-50 ultrasound,41–43 magnetic field47-48 and 
endogenous stimuli – pH,51-52 redox53–55 and enzyme56-57 that are utilized for drug delivery. Among 
the endogenous stimuli, redox sensitive systems are convenient to exploit, as disulfide bonds can 
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be cleaved in the presence of a reducing agent like glutathione which is present at a significantly 
higher concentration inside the cytosol (~ 2-10 mM) compared to its extracellular (~ 2-10 µM) 
concentration. 89-90 Introducing disulfide crosslinking in the hydrophobic core serves two purposes. 
Firstly, it can incarcerate the drug further and improve the stability, and secondly it provides an 
opportunity for releasing the drug upon reaching the cytosol.  
 We have previously reported in our lab, a self-crosslinked nanogel system in which the 
amphiphilic random copolymer consists of oligo ethyleneglycol as the hydrophilic unit which 
helps in increasing circulation time in blood by reducing nonspecific interaction with serum 
proteins and is biocompatible; and pyridyl disulfide as the hydrophobic unit which is reactive to 
thiols and can form disulfide crosslinks to form nanogels in aqueous systems. This system showed 
many useful properties like size tunability, control over drug release kinetics by varying crosslink 
density, ability to surface functionalize with cell penetrating peptides etc.38-39-91-92   
 Considering all these necessary requirements for developing an ideal drug delivery carrier, 
we were inspired by the self-crosslinked nanogel system that we developed and wanted to probe 
the drug loading property. In this work, we have designed a self xlinked nanogel system based on 
amphiphilic block copolymer consisting of poly ethyleneglycol (PEG) as the hydrophilic unit and 
pyridyl disulfide as the reactive hydrophobic unit which can crosslink in the presence of a thiol 
like Dithiothreitol (DTT) as shown is Scheme 3.1. The disulfide crosslinked nanogel system is 
also responsive to biologically relevant stimuli glutathione which is present in significantly higher 
concentrations in the cytosol than the blood. We have also proposed convenient methods to 
quantify drug loading in crosslinked nanoparticles since crosslinked polymers are difficult to 
dissolve in solvents especially the ones used for High Performance Liquid Chromatography 
(HPLC).93–96 
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3.2 Results and Discussion  
3.2.1 Design and Synthesis  
The amphiphilic block copolymer was obtained by RAFT polymerization using 
Polyethylene glycol (PEG) as the macro RAFT chain transfer reagent and Pyridyl disulfide ethyl 
methacrylate (PDSEMA, 2).  Block copolymers with different PEG and PDSEMA ratios were 
obtained by using PEG macro RAFT chain transfer reagent with different molecular weights and 
by varying the molar ratios of PDSMEA, Table 3.1. The repeat units of PDSMEA in the block 
copolymer was determined by 1H-NMR spectroscopy by comparing the integration of the aromatic 
proton from PDSME at 8.5 ppm to the end group methyl proton from PEG at 3.3 ppm as shown 
in Figure 3.1. 
Scheme 3. 1 (a) Schematic representation of the preparation of the nanogels. (b) Structure of the 
polymer precursors and nanogels. 
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Figure 3. 1 The polymerization of PEG-PDS block copolymer and 1H NMR spectra of PEG-PDS 
block copolymer. 
 
 
 
 
3.2.2 Self Assembly Characterization 
 As the polymer has both hydrophilic and hydrophobic units, we hypothesized that the 
amphiphilic polymer will self-assemble in aqueous solution. Since the polymer was not readily 
dispersible in water, tetrahydrofuran (THF) was used as a co-solvent and the assemblies were 
Table 3. 1 Size distribution of polymer aggregate with varying 
PEG and PDS ratios. 
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obtained by the process of nanoprecipitation. Dynamic Light Scattering (DLS) and Transmission 
Electron Microscopy (TEM) were utilized to study the size and morphology of the polymer 
aggregates. Only polymers with PEG Mn 5400 and less than 10 repeat units of PDS formed 
assembles less than 100 nm, Table 3.1.  Polymers with PEG Mn 10000 and 1400 were not readily 
soluble in THF and had to be dissolved in dimethlyformamide (DMF) instead. The larger 
aggregates obtained with PEG 10,000 is hypothesized to be due to the low solubility and high 
viscosity of the longer PEG chains.97-98 The larger aggregates obtained with PEG Mn 1400 is 
hypothesized to be due to the imbalance of the hydrophilic and hydrophobic units. The sizes of the 
assemblies formed with PEG Mn 5400 with 5 and 7 repeat units of PDS were ~23 and ~34 nm 
respectively, as seen by DLS. TEM showed well defined micelle like spherical aggregates with 
slightly bigger size which is presumably due to aggregation during solvent evaporation while 
drying, Figure 3.2. The combined observations from DLS and TEM measurements reveal that the 
block copolymers P1 and P2 form micelle like aggregates in aqueous solution.  For all further 
analysis P1 was utilized unless specified. 
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 It has been previously reported that change in the volume fraction of THF can cause a 
change in the size of the nanoparticle formed from a block copolymer.99-100 This is because when 
both the hydrophobic and hydrophilic segments of the block copolymer are dissolved in THF, the 
self-assembly process proceeds via the process of equilibration where the molecules are free to 
exchange with the bulk solvent. But as the volume fraction of THF is decreased, there reaches a 
stage where the hydrophobic block becomes glassy and is considered frozen. The aggregation 
number of the micelle aggregates cannot be altered beyond this point. We therefore wanted to test 
this effect for the block copolymer we synthesized and observed that when we varied the volume 
fraction of THF from 50 to 400 uL per mL there was no change observed in the sizes of the 
assemblies as seen in Figure 3.3. 
 
 
Figure 3. 2 Self-assembly of polymeric aggregates as seen 
by a) Dynamic Light Scattering, b) Transmission Electron 
Microscopy (scale 500nm). 
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3.2.3 Nanogel Formation and Characterization                                                                                            
 The next thing we tested was crosslinking the block copolymer aggregates using 
dithiothreitol (DTT). Briefly, a deficient amount of DTT is added to an aqueous solution of 
polymer aggregates. DTT can react with PDS and generate a thiol. The thiol generated can then 
react with the remaining PDS groups in the polymer chain to generate a crosslinked polymeric 
nanogel system. This crosslinking reaction is monitored by the production of pyridothione which 
has a characteristic absorption at 343 nm, Figure 3.4. We observed that the crosslinking efficiency 
of block copolymer aggregates was significantly less efficient than what we observed for random 
copolymers.38 Interestingly, the crosslinking efficiency was worse for block copolymer with longer 
PEG chain Mn 5400, Figure 3.4. The inefficient crosslinking efficiency is assumed to be due to 
either the high viscosity of longer PEG chains which is known to increase significantly with 
increase in chain length or due to the rigid and glassy hydrophobic core of the assemblies formed 
by the block copolymers.  
 
Figure 3. 3 Effect of THF co-solvent on the size of 
assemblies formed in water as seen by Dynamic Light 
Scattering technique. 
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3.2.4 Methods to quantify drug loading 
 A majority of the anti-cancer and therapeutic drugs are poorly soluble in aqueous media.101-
102 Therefore, we chose drugs that are hydrophobic – Doxorubicin, Docetaxel, Paclitaxel and 
Rapamycin which have different LogP values Figure 3.6. Amongst these, only Doxorubicin has 
fluorescence and absorbs light in the visible spectrum. Drugs that absorb light in the visible region 
are easier to quantify because they can be conveniently quantified using UV/vis spectrophotometer 
without having to use HPLC. However, HPLC is widely used to quantify drugs in nanoparticles 
that absorb light in the Ultraviolet region. It is crucial to note the assumption for quantifying drug 
loading in nanoparticles by HPLC is that the drug is completely isolated/extracted while dissolving 
it in the solvent which is the mobile phase.  Chemically crosslinked nanoparticles are however 
typically insoluble in solvents that are commonly used for HPLC94-96 and we have proposed new 
strategies to quantify drug loading in chemically crosslinked nanogels. We have designed two 
methods to quantify the amount of non-encapsulated drug and one method to calculate the amount 
of encapsulated drug. 
Figure 3. 4 Moles of DTT required for crosslinking polymer aggregates with PEG and PDS 
with different ratios. 1X represents the theoretical amount of DTT required for 100% xlinking. 
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3.2.4.1 Analyzing non-encapsulated drug 
 Since three of the drugs that we want to analyze for drug loading are hydrophobic, we have 
designed convenient strategies to analyze the non-encapsulated drugs.  
3.2.4.1.1 Analyzing non-encapsulated drug: Pelleting the non-encapsulated drug 
 
  
 
The water solubility of Docetaxel, Paclitaxel and Rapamycin is less than 20 µM.103–105 When the 
initial feed ratio of drug loaded is high enough and there is a percentage of drug that does not get 
encapsulated, it crashes out of the aqueous solution owing to its poor water solubility. Since the 
nanoparticles made from block copolymers P1 is less than 100 nm, we envisaged using Centrifuge 
to pellet down the non-encapsulated drug and thus quantify the amount of drug encapsulated by 
back calculation. We optimized the centrifuge speeds such that only the non-encapsulated drug 
pellets down excluding the nanoparticles. Finding this balance was easier for nanoparticles that 
were smaller in size - less than 100 nm. Isolating the non-encapsulated drug from nanoparticles 
that were bigger than 100 nm i.e. the assemblies formed from block copolymers P3-P5 was rather 
challenging and hence we established that this method is suitable for nanoparticles that are less 
than 100 nm. 
Scheme 3. 2 Pictorial representation of drug quantification by pelleting the non-
encapsulated drug. 
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 Next, we were interested in studying the effect of crosslinking on the loading values of 
nanoparticles. During crosslinking, we have two processes occurring concurrently – i) cleaving of 
the pyridothione moiety which reduces the hydrophobicity and potentially reduces the drug 
loading efficiency and ii) introduction of disulfide bonds which can physically incarcerate the 
hydrophobic guest/drug. These two competing processes dictate the final drug loading efficiency 
in crosslinked nanogels. We observed that for 0, 33, 67 and 90% crosslinked nanogels P1 there 
was no significant difference in drug loading efficiency Figure 3.7. This is possibly due to both 
the competing effects of crosslinking having a similar effect which finally does not alter the 
loading efficiency. The pelleting method was used to quantify drug loading. 
 
3.2.4.1.2 Analyzing non-encapsulated drug: Isolating drug from the syringe filter 
 
 
 
 When hydrophobic dyes or drugs are loaded onto nanoparticles, the non-encapsulated 
dyes/drugs are removed by first passing the nanoparticle solution through a syringe filter with an 
appropriate pore size. We utilized this technique to trap the non-encapsulated hydrophobic drug. 
Since the drug is hydrophobic, the non-encapsulated drug crashes out of the aqueous solution as 
Scheme 3. 3 Pictorial representation of drug quantification by isolating the non-encapsulated 
drug using a syringe filter. 
		
	
68 
shown in Scheme 3.3. We can then pass the solution through a syringe filter and wash the filter to 
rinse out any residual nanoparticle solution. The trapped drug can then be isolated by passing 
organic solvent which is compatible with the syringe filter, and also dissolves the drug. The drug 
can finally be quantified using UV/Vis spectrophotometer or HPLC.  This method could also have 
been used for nanoparticles that form bigger assemblies because we could use appropriate filters 
in each case. To ensure that there is no nanoparticle hold up in the syringe filter which would 
underestimate drug loading values, we analyzed the syringe filter residue by 1H-NMR after passing 
the nanoparticle solution through it. While analyzing the nanoparticle solution constituted from 
polymer P3, we utilized 1.1 µm syringe filter and noticed that there was a significant amount of 
polymer stuck in the filter as seen by 1H NMR obtained from analyzing the filter residue as seen 
in Figure 3.5. We however, did not observe any polymer peak when analyzing the nanoparticle 
solution constituted from polymer P2. This method again rendered useful for nanoparticles that 
formed smaller assemblies. 
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Figure 3. 5 1H NMR of syringe filter residue after passing the specified polymers. Control 
denotes blank acetone passed through the syringe filter without any polymer. 
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3.2.4.2 Analyzing encapsulated drug 
 
 
 The block co-polymer has an absorbance in the UV region which overlaps with the 
absorption spectra of Docetaxel, Paclitaxel and Rapamycin. This is the reason why quantifying 
drugs loaded in nanoparticles by UV/Vis spectrophotometer becomes challenging. We however 
designed an ingenuous way of using UV/Vis spectroscopy to quantify drug loading. If we take a 
control sample with the same amount of polymer without the drug and measure that as the blank 
reading, we would zero the absorption spectra of the polymer that would potentially overlap with 
the drug. Now when we measure the drug loaded in the same amount of polymer/nanoparticle, we 
will only be recording the absorption spectra of the drug in the UV region. This method is 
convenient however it is crucial that the amount of polymer in the blank is exactly the same as the 
drug loaded sample. This method was challenging to use for crosslinked nanogels because if the 
by-product of crosslinking, pyridothione is not dialyzed away completely, that would interfere 
with the absorption spectra of the drug loaded samples. 
 Briefly as shown in Scheme 3.4, the non-encapsulated drug is first removed by either 
centrifuge or using a syringe filter followed by dialysis to remove any loosely bound drug. The 
Scheme 3. 4 Pictorial representation of encapsulated drug quantification using UV/Vis 
spectrophotometer. 
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drug loaded nanoparticle solution is then lyophilized and reconstituted in DMSO (a solvent in 
which the polymer does not form assemblies) and analyzed by UV/Vis spectrophotometer. 
3.2.5 Drug loading values 
For nanoparticles that formed smaller assemblies (<100 nm); the pelleting method was 
found to be the most convenient method to analyze drug loading. The loading values of 
Rapamycin, Paclitaxel and Docetaxel drugs were found to be high for initial feed weight ratio of 
40% of the drug. We observed that there wasn’t a significant difference in the drug loading values 
between these three drug that have different LogP values. Paclitaxel was found to have the highest 
loading understandably due to the 3 aromatic rings in the molecule that could contribute to the 
aromatic interaction with the nanogel core which consists of pyridyl groups.  We also analyzed the 
loading values using different methods and found that they were similar. And as previously 
explained, the crosslinking had no effect on the drug loading values.  
 
Figure 3. 6 Structures of the drugs with varying LogP values and the loading capacities of 
Rapamycin, Paclitaxel and Docetaxel measured by pelleting method and Doxorubicin using 
UV/Vis calibration. 
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3.2.5.1 Effect of increased drug loading 
 We wanted to test the possibility of increasing drug loading by varying the initial feed ratio 
of the drug loaded. Drug loading capacity of the nanoparticles increased from 9% to 30% when 
Paclitaxel was used as the drug and the syringe filter method was used to analyze drug loading. 
The loading efficiency decreased from 90% to 75% as we increased the drug loading. The decrease 
in drug loading efficiency can be explained by the decrease in available volume/space in the 
nanoparticle core once an optimal saturating loading has been attained. We also observed greater 
amounts of precipitation of the drug when the loading was increased above 40%. 
 
 
 
 
Figure 3. 7 Loading capacity and efficiency of Paclitaxel and Docetaxel using different 
methods - the pelleting method (a and c), syringe filter isolation (b) and UV/Vis (c). 
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It has been reported previously that the size of the nanoparticles after drug loading increases 
due to drug entrapment.106 We observed a slight increase in the size of the nanoparticles when the 
loading of paclitaxel was increased from 10% to 40%. However, the correlation function of the 
particles gradually became weaker with higher drug loading understandably as the integrity of the 
particles get compromised with high loading of the drugs due to swelling.  
 
 
3.2.6 Cell survival  
We investigated the in vitro efficiency of the drug loaded nanoparticles in human prostate 
cancer cell line, DU-145. For comparison, the same concentration of drugs was used as a control 
without the nanoparticle. Using Alamar Blue cell viability assay we observed that, after incubating 
Table 3. 2 Loading values of Paclitaxel with 
increased feed ratios. 
Figure 3. 8 Sizes of the assemblies with increased Paclitaxel loading values as 
seen by Dynamic Light Scattering. 
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the drug loaded nanoparticles for 48 hours on a 96 well plate seeded with DU-145 cell line, the 
cell viability or the cell survival rate with or without the nanoparticle was comparable. The final 
concentration of each drug was 0.5 µM.  
 
 
We were also interested in investigating the effect of crosslink density on the cell survival 
rates as we hypothesized that the higher crosslinked nanogels would provide a tighter protection 
against drug release. To test this, we loaded paclitaxel in nanoparticles that were crosslinked with 
different percentages. The amount of Paclitaxel loaded in the crosslinked nanogels were the same.   
We tested this for three different concentrations of Paclitaxel and observed that cell survival was 
slightly better for the higher crosslinked nanogels for all the concentrations tested. We reason that 
the tightly crosslinked nanogels provide a tighter assembly for the drugs encapsulated and the 
release of these drugs is less efficient and thus the cell survival better. 
Figure 3. 9 Cell viability of drug loaded nanogels on DU-145 cell lines. 
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We also investigated the time dependent cytotoxicity of Paclitaxel loaded nanoparticles. 
We incubated the control free drug and Paclitaxel loaded nanoparticles with cells DU-145 over 12, 
24 and 48 hours and observed that the cytotoxicity was enhanced over time and the efficiency for 
Paclitaxel loaded nanoparticles were comparable to free Paclitaxel at 0.1 µM concentration, tested 
at all the incubation times.  
Figure 3. 10 a) Cell viability of Paclitaxel loaded nanogels with varying crosslink density and 
concentration of Paclitaxel (1, 10 and 100  µM) and b) Comparison of cytotoxicity of Paclitaxel 
loaded in nanogels with varying crosslink densities. 
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3.3 Summary 
 In summary, we have utilized the superior drug loading property of block copolymers to 
redesign our previously developed crosslinked nanogel system based on hydrophilic polyethylene 
glycol and hydrophobic pyridyl disulfide groups. We also developed methods to quantify drug 
loading in crosslinked polymeric nanogels. The disulfide crosslinked nanogel showed high 
encapsulation efficiencies for therapeutic drugs with varying LogP values. The drug encapsulated 
nanogels also showed efficient cell killing which was comparable with the free drug. We also 
attempted to study the structure property relationship between the different drugs with varying 
LogP values and the drug loading efficiencies. The target specific, redox responsive crosslinked 
nanogel system with high drug loading efficiency has promising potential for in vivo use.   
 
 
 
 
Figure 3. 11 Time dependent cell viability of 0.1 µM Paclitaxel loaded nanogels with varying 
crosslink densities. 
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3.4 Experimental Details 
3.4.1 Materials and Methods 
All the reagents were purchased from commercial source and used as such without further 
purification. 1H NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer using the 
residual proton resonance of the solvent as the internal standard. Chemical shifts (δ) are reported 
in parts per million (ppm) and Hertz, respectively. The following abbreviations are used for the 
peak multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublet; 
bs, broad singlet; bd, broad doublet; bm, broad multiplet. 13C-NMR spectra were recorded on a 
400MHz Bruker NMR spectrometer using carbon signal of the deuterated solvent as the internal 
standard. Dynamic Light Scattering (DLS) measurements were carried out on a Malvern 
Nanozetasizer. TEM images were recorded on a JEOL-2000FX machine operating at an 
accelerating voltage of 100 kV. Molecular weights of the polymers were estimated by gel 
permeation chromatography (GPC) using PMMA standard with a refractive index detector. 
Fluorescence measurements were performed on a fluorescence plate reader (Molecular Devices, 
SpectraMax M5). High performance liquid chromatography was conducted using a Shimadzu 
Prominence Modular reverse phase High Performance Liquid Chromatography (HPLC) with a 
C18 column (Length – 10 cm, Inner diameter – 4.6 mm, Particle size 2.5 µm and 90 Å pore size). 
Thermogravimetric analysis (TGA) was performed using a TGA Q500 system from TA 
Instruments Inc. under a N2 atmosphere from RT- 600 °C at a heating rate of 5 °C /min. 
Differential Scanning Calorimetry (DSC) was performed using a DSC Q200 RCS system from TA 
Instruments Inc. with refrigerated Cooling System. The sample was heated with constant ramp rate 
of 10 °C/min between -30 °C and 150 °C. 
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3.4.2 Synthesis Procedures and Characterization of Molecules 
 
 
Synthesis of compound 3: 
 
 
2,2'-Dipyridyldisulfide Aldrithiol-2, 7 (11.25g, 0.0511 mol) was dissolved in 50 mL of 
methanol and 0.5 mL of glacial acetic acid was added to it. To this mixture, a solution of 
mercaptoethanol (1.99 mL, 0.0255 mol) in 15 mL methanol was added drop-wise at room 
temperature with continuous stirring. Once the addition was over, the reaction mixture was stirred 
at room temperature for additional 3 h. The stirring was stopped, solvent was evaporated to get the 
crude product as yellow oil which was purified by flash column chromatography using silica gel 
as stationary phase and mixture of ethyl acetate/hexane as eluent. The excess aldrithiol came out 
first at 15% ethyl acetate/hexane mixture, then the polarity of the eluent was increased to 40% 
ethyl acetate/hexane to get the desired product as colorless oil. Yield: 70% 1H NMR: (CDCl3, 400 
N S
S
OH
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MHz), δ (ppm): 8.43 (m, 5H), 7.61 (m, 1H, aromatic proton meta-N), 7.48 (m, 1H,), 7.16 (m, 1H), 
3.82 (t, 2H), 2.95 (t, 2H) 
Synthesis of monomer 4: 
 
To a solution of compound 3 (3.3 g, 17.6 mmol) in 20 mL of dry dichloromethane was 
added 2.67 g (26.47 mmol) of triethylamine and the mixture was cooled in an ice-bath. To this 
cold mixture, a solution of methacryloyl chloride (2.76g, 26.47 mmol) in 10 mL dichloromethane 
was added drop-wise with continuous stirring. After the addition was over the reaction mixture 
was stirred at room temperature for 6 h. The stirring was stopped and the reaction mixture was 
washed with 3x30 mL distilled water and then with 30 mL of brine. The organic layer was 
collected, dried over anhydrous Na2SO4 and concentrated to get the crude product as yellow oil. It 
was purified by column chromatography using silica gel as stationary phase and mixture of ethyl 
acetate/hexane as eluent. The pure product was collected at 25% ethyl acetate /hexane. Yield: 80% 
1H NMR: (CDCl3, 400 MHz), δ (ppm): 8.52 (m, 1H), 7.62-7.83 (m, 2H), 7.15 (m, 1H), 6.23 (d, 
1H), 5.65(d, 1H) 4.41 (t, 2H), 3.13 (t, 2H), 1.91(s, 3H). 
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Synthesis of Polymer P1 
 
PDSEMA, 4 (80 mg, 0.313 mmol), Poly (ethylene glycol) methyl ether (4-cyano-4-
pentanoate dodecyl trithiocarbonate), 1 (169 mg, 0.0313 mmol) and AIBN (1 mg, 0.00626 mmol) 
were weighed and dissolved with 400 µL THF in a 7-mL glass scintillation vial and sealed with a 
rubber septum. The flask was purged with argon and performed three freeze-pump thaw cycles. 
The reaction vial was then transferred to an oil bath preheated at 65 °C. The polymerization was 
quenched after 24 h by cooling down the reaction flask with cold water and the viscous reaction 
product was purified by precipitation in diethyl ether to yield the random copolymer as an off 
white solid. 
Polymer P1 1H NMR: (CDCl3, 400 MHz), δ (ppm): 8.43 (5H), 7.62 (10H), 7.06 (5H), 4.19 (11H), 
3.78-3.43 (498H), 3.35 (3H), 3.00 (10H), 2.14-1.7 (16H), 1.22 (22H), 1.03(5H), 0.86 (10H). 
Integration of the methoxy proton (in PEG unit at 3.35 ppm) and the aromatic proton (in pyridine 
unit at 8.43 ppm) provided the molar ratio of two monomers to be 1:5 (PEG/PDS). 13C NMR 
(400MHz, CDCl3) δ(ppm):  159.6, 149.5, 137.4, 121.1, 119.9, 71.9, 70.0, 61.7, 58.7, 44.5, 36.6, 
31.6, 29.4, 22.3, 14.1. 
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Polymer P2 1H NMR: (CDCl3, 400 MHz), δ (ppm): 8.43 (7H), 7.62 (14H), 7.06 (7H), 4.19 (12H), 
3.78-3.43 (460H), 3.35 (3H), 3.00 (12H), 2.14-1.7 (14H), 1.22 (24H), 1.03(8H), 0.86 (12H). 
Integration of the methoxy proton (in PEG unit at 3.35 ppm) and the aromatic proton (in pyridine 
unit at 8.43 ppm) provided the molar ratio of two monomers to be 1:7 (PEG/PDS). 13C NMR 
(500MHz, CDCl3) δ(ppm):  159.6, 149.5, 137.4, 121.1, 119.9, 71.9, 70.0, 61.7, 58.7, 44.5, 36.6, 
31.6, 29.4, 22.3, 14.1. 
Polymer P3 1H NMR: (CDCl3, 400 MHz), δ (ppm): 8.43 (16H), 7.62 (32H), 7.06 (16H), 4.19 
(32H), 3.78-3.43 (66H), 3.35 (3H), 3.00 (32H), 2.14-1.7 (32H), 1.22 (32H), 1.03(20H), 0.86 (28H). 
Integration of the methoxy proton (in PEG unit at 3.35 ppm) and the aromatic proton (in pyridine 
unit at 8.43 ppm) provided the molar ratio of two monomers to be 1:16 (PEG/PDS). 13C NMR 
(500MHz, CDCl3) δ(ppm):  159.6, 149.5, 137.4, 121.1, 119.9, 71.9, 70.0, 61.7, 58.7, 44.5, 36.6, 
31.6, 29.4, 22.3, 14.1. 
Polymer P4 1H NMR: (CDCl3, 400 MHz), δ (ppm): 8.43 (10H), 7.62 (20H), 7.06 (10H), 4.19 
(25H), 3.78-3.43 (60H), 3.35 (3H), 3.00 (22H), 2.14-1.7 (27H), 1.22 (22H), 1.03(15H), 0.86 (20H). 
Integration of the methoxy proton (in PEG unit at 3.35 ppm) and the aromatic proton (in pyridine 
unit at 8.43 ppm) provided the molar ratio of two monomers to be 1:10 (PEG/PDS). 13C NMR 
(500MHz, CDCl3) δ(ppm):  159.6, 149.5, 137.4, 121.1, 119.9, 71.9, 70.0, 61.7, 58.7, 44.5, 36.6, 
31.6, 29.4, 22.3, 14.1. 
Polymer P5 1H NMR: (CDCl3, 400 MHz), δ (ppm): 8.43 (10H), 7.62 (20H), 7.06 (10H), 4.19 
(14H), 3.78-3.43 (60H), 3.35 (3H), 3.00 (12H), 2.14-1.7 (16H), 1.03(16H), 0.86 (24H). Integration 
of the methoxy proton (in PEG unit at 3.35 ppm) and the aromatic proton (in pyridine unit at 8.43 
ppm) provided the molar ratio of two monomers to be 1:10 (PEG/PDS). 13C NMR (500MHz, 
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CDCl3) δ(ppm):  159.6, 149.5, 137.4, 121.1, 119.9, 71.9, 70.0, 61.7, 58.7, 44.5, 36.6, 31.6, 29.4, 
22.3, 14.1. 
3.4.3 Other Experimental Protocols 
3.4.3.1 Dynamic Light Scattering (DLS) Study 
DLS was performed on a Malvern Nano-zeta sizer instrument with a 637 nm laser source 
with non-invasive backscattering technology detected at 173⁰. All sizes are reported as the 
hydrodynamic diameter (DH) and were repeated in triplicate. For the DLS measurements, the 
concentration of the polymer and nanogel solution was 0.5 mg/mL unless specified. 
3.4.3.2 Transmission Electron Microscope (TEM) Study 
For the TEM measurements the polymer solution was prepared in 0.5 mg/mL 
concentration. One drop of the sample (10 µL) was drop-casted on carbon coated Cu grid, 400 
mesh size and left to dry overnight.  
3.4.3.3 In vitro Cell Viability/cytotoxicity 
To study the cytotoxic effect of released drugs from the polymer nanoparticles, DU145 
cells were seeded in 96-well tissue culture plates at a density of 5000 cells/well/100 µL sample 
and incubated at 37 °C and 5% CO2. The cell culture media was replaced after 24 h and cells were 
treated with different concentrations of drug encapsulated polymer nanoparticles and control drug 
samples (individual drug concentrations of 0.1 and 0.5 µM in both control and drug encapsulated 
polymer samples). For empty nanoparticles, the polymer concentrations were matched with the 
encapsulated ones. After treatment, samples were incubated for 12 and 24 h at 37 °C and 5% CO2. 
Afterwards media was replaced, washed with PBS buffer for three times and each well was treated 
with 100 µL 10% Alamar Blue reagent in media with serum. Finally, all samples were incubated 
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for 1.5 h and transferred to a black 96-well flat-bottomed plate for fluorescence measurement with 
SpectraMax® M5 at 560 nm excitation/590 nm emission wavelengths. 
3.4.3.4 Procedure for dye encapsulation  
The polymer (0.5 mg/mL) was dissolved in water. 10 µL (0.01 mg) of DiI (1mg/mL in 
acetone) was added to the stirring solution of polymer followed by the desired amount of DTT for 
crosslinking. The mixture was stirred overnight at room temperature, open to the atmosphere 
allowing the organic solvent to evaporate. Excess insoluble DiI was removed by filtration and 
pyridothione was removed from the nanogel solution by dialysis using a membrane with molecular 
cut-off of 3.5 kDa. 
3.4.3.5 HPLC protocol for Rapamycin 
High performance liquid chromatography was conducted using a Shimadzu Prominence 
Modular reverse phase High Performance Liquid Chromatography (HPLC) with a C18 column 
(Length – 10 cm, Inner diameter – 4.6 mm, Particle size 2.5 µm and 90 Å pore size) using 
Methanol: water as the mobile phase both containing 0.05% (v/v) trifluoroacetic acid starting with 
80% Methanol and gradually increasing it to 100% over 15 minutes with the flow rate of 1 mL/min 
and the detection wavelength of 230/277 nm.  
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3.4.3.6 HPLC protocol for Paclitaxel 
High performance liquid chromatography was conducted using a Shimadzu Prominence 
Modular reverse phase High Performance Liquid Chromatography (HPLC) with a C18 column 
(Length – 10 cm, Inner diameter – 4.6 mm, Particle size 2.5 µm and 90 Å pore size) using 
Acetonitrile: water as the mobile phase both containing 0.05% (v/v) trifluoroacetic acid starting 
with 40% Acetonitrile and gradually increasing it to 100% over 15 minutes with the flow rate of 1 
mL/min and the detection wavelength of 230/268 nm.  
Figure 3. 12 HPLC calibration curve of Rapamycin. 
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3.4.3.7 HPLC protocol for Docetaxel 
High performance liquid chromatography was conducted using a Shimadzu Prominence 
Modular reverse phase High Performance Liquid Chromatography (HPLC) with a C18 column 
(Length – 10 cm, Inner diameter – 4.6 mm, Particle size 2.5 µm and 90 Å pore size) using 
Acetonitrile: water as the mobile phase both containing 0.05% (v/v) trifluoroacetic acid starting 
with 40% Acetonitrile and gradually increasing it to 100% over 15 minutes with the flow rate of 1 
mL/min and the detection wavelength of 230/268 nm. 
Figure 3. 13 HPLC calibration curve of Paclitaxel. 
		
	
86 
 
 
 
 
 
 
 
 
 
 
 
3.4.3.8 Procedure for drug encapsulation (Rapamycin, Paclitaxel and Docetaxel) 
0.5 mg of polymer was weighed in a 7-mL glass scintillation vial and 100 uL of THF was 
added to it. This solution was stirred using a magnetic stir bar till the polymer completely 
dissolved. Drug stock solution were freshly prepared in THF and 100 uL of the drug stock solution 
was added to the polymer solution for the appropriate drug loading percentage values to finally 
contain 200 uL of THF. 1 mL of distilled water was added dropwise to a stirring solution of 
polymer and drug using a syringe needle with a 22 Gauge X 1 1/2 (0.7 mm X 40 mm). The solution 
was left stirring at least for 12 hours without a cap to let the THF evaporate.  
Figure 3. 14 HPLC calibration curve of Docetaxel. 
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3.4.3.9 Procedure for drug encapsulation (Doxorubicin) 
0.5 mg of polymer was weighed in a 7-mL glass scintillation vial and 100 uL of Dimethyl 
sulfoxide (DMSO) was added to it. This solution was stirred using a magnetic stir bar till the 
polymer completely dissolved. Doxorubicin free base was used as purchased. Doxorubicin stock 
solution were freshly prepared in DMSO and 100 uL of the drug stock solution was added to the 
polymer solution for the appropriate drug loading percentage values to finally contain 200 uL of 
DMSO. 1 mL of distilled water was then added dropwise to a stirring solution of polymer and 
Doxorubicin using a syringe needle with a 22 Gauge X 1 1/2 (0.7 mm X 40 mm). The solution 
was left stirring for at least 6 hours followed by dialysis using a snakeskin membrane with a 3.5 
kDa molecular weight cutoff. Doxorubicin encapsulation was calculated by making a calibration 
curve of Doxorubicin in 100 µL DMSO and 500 µL water.  
   
 
 
 
Figure 3. 15 Calibration curve of Doxorubicin using UV/Vis 
spectrophotometer. 
		
	
88 
 
3.4.3.10 Drug Loading efficiency and capacity 
Drug loading efficiency and capacity were calculated using the following equations 
Loading efficiency = !"#$%&	()	&%"	"*+,-./0,&"1	12/$		!"#$%&	()	&%"	12/$	#*#&#,003	,11"1 
Loading capacity = !"#$%&	()	&%"	"*+,-./0,&"1	12/$!"#$%&	()	&%"	-(034"2  
3.4.3.11 Procedure for isolating drug (Rapamycin, Paclitaxel and Docetaxel) with the 
pelleting method 
Following the procedure for drug encapsulation, the solution was transferred to a 15 mL 
Falcon conical centrifuge tube with an addition of 5 mL of water. The solution was centrifuged at 
2.2 k RPM for 10 minutes to collect the pellet. The pellet was washed with 6 mL water and 
centrifuged again. The pellet was then lyophilized before reconstituting it in DMSO for HPLC or 
UV/Vis analysis. 
3.4.3.12 Procedure for isolating drug (Rapamycin, Paclitaxel and Docetaxel) using syringe 
filter 
Following the procedure for drug encapsulation, the solution was passed through a nylon 
syringe filter with different pore sizes -  0.45 µm, 1.5 µm and 10 µm with Double Luer Lock. At 
least 10 mL of water was then passed through the syringe filter to wash the nanoparticle solution. 
The filter was then washed with 5 mL of acetone and the drug recovered by evaporating acetone 
using rotary evaporator before reconstituting it in DMSO for HPLC or UV/vis analysis.  
3.4.3.13 Procedure for analyzing the drug using UV/Vis spectrophotometer 
Following the procedure for drug encapsulation, the non-encapsulated drug was removed 
by either the pelleting method or using a syringe filter. The solution was then lyophilized and 
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reconstituted in DMSO. As the blank sample, the same amount of polymer was used to make 
nanoparticles but without the drug. This was used as the blank reading for measuring drug loading 
by UV/Vis spectrophotometer.  
 
3.4.3.14 Procedure for nanogel formation 
Followed a reported procedure 38 
Crosslinking efficiency: 
In order to determine the crosslinking percentage efficiency, UV-vis measurements were 
performed with samples of the solution reacted with DTT. Once this was measured, we calculated 
the amount of pyridothione based on its known molar extinction coefficient (8.08 x 103 M-1 cm-1 
at 343 nm).  The percentage of cross-linking was calculated by assuming that formation of a single, 
crosslinking disulfide bond would require cleavage of two PDS units and produce two 
pyridothione molecules.            
         
 
 
 
Figure 3. 16 Calibration curve of Paclitaxel and Docetaxel using UV/Vis spectrophotometer. 
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3.4.4 1H- NMR 
*: solvent residues are marked with stars. 
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Figure 3. 17 1H-NMR spectra of P1 
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Figure 3. 18 1H-NMR spectra of P2 
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Figure 3. 19 1H-NMR spectra of P3 
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Figure 3. 20 1H-NMR spectra of P4 
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Figure 3. 21 1H-NMR spectra of P5 
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3.4.5 13C- NMR 
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Figure 3. 22 13C-NMR spectra of P1 
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 Figure 3. 23 13C-NMR spectra of P2 
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Figure 3. 24 13C-NMR spectra of P3 
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 Figure 3. 25 13C-NMR spectra of P4 
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Figure 3. 26 13C-NMR spectra of P5 
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3.4.6 TGA and DSC curves 
 
 
 
 
 
 
Figure 3. 27 TGA curve of P1: the first weight loss slope indicates 
the PDS groups degrading (between 170 and 240 ºC) and the second 
weight loss slope indicates the PEG group's degradation (330 to 420 
ºC). 
Figure 3. 28 DSC curve of P1: a melting endotherm at 60 ºC (during 
the heating cycles) and a recrystallization exotherm at 30 ºC (during 
the cooling cycle). 
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3.4.7 GPC chromatogram 
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CHAPTER 4 
CHARGE-TUNABLE, REDOX RESPONSIVE POLYMERIC NANOCARRIER FOR 
siRNA DELIVERY 
4.1 Introduction 
 There are over a thousand diseases that are caused by gene mutations.71-107 After the 
completion of the human genome project which started in 1990 and finished in 2013, the plethora 
of genetic information that was gathered has helped scientists better understand the molecular 
mechanisms that govern diseases which are caused by gene modification. Gene therapy has 
progressed significantly over the last decade where therapeutic genes are used as drugs to cure 
diseases.108-109 Till date there are more than 2600 clinical trials that were approved for gene therapy 
out of which more than 64% were for cancer.110-111 The several experimental ways to approach 
gene therapy involves replacing defective genes with a healthy copy, knocking down defective 
genes or overexpressed genes and implanting new genes that can help fight a disease.112–115 Gene 
modification can be brought at the transcriptional or the translational level.  
 RNA interference (RNAi) is a natural phenomenon observed in eukaryotes where double 
stranded RNAs of viral origin are downregulated.116–118 This process has been developed and 
employed by biologists to downregulate or knockdown the targeted diseased genes in a sequence 
specific strategy. RNA interference works by first processing the ds DNA or dsRNA to smaller 
segments called short interfering RNAs (siRNAs) by the enzyme Dicer.119–122 This activates the 
siRNA binding to the RNA – induced multiprotein complex, a process in which the double 
stranded siRNA is unwound into a single strand before binding with the RISC complex. This single 
stranded siRNA can then bind with the complementary mRNA which is followed by the 
degradation of mRNA by the protein Argonaute, one of the proteins of the RISC complex. 
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Degradation of mRNA inhibits the translation to the complimentary protein. Using siRNA instead 
of dsDNA or dsRNA can bypass the step where Dicer cleaves the long DNA or RNA, which offers 
the advantage of target specificity.123–125  
 Delivering naked nucleic acids is very challenging because they rapidly get degraded in 
the plasma by nucleases.72 Therefore, there are delivery vectors that are used for transfecting them 
inside the cells. They are mainly categorized into non-viral and viral vectors. More than 65% of 
the gene therapy clinical trials use viral vectors. They are the most efficient in transfecting cells 
with genes because of their inherent cell uptake mechanism. However, there is a growing concern 
of immunogenicity that is associated with the repeated administration of virus.74-75-126 The non-
viral vectors include dendrimers, polymers, liposomes, cell penetrating peptides etc.127–133 
Amongst the non-viral vectors, cationic polymers hold an advantage of easy and inexpensive 
synthesis and high loading capabilities. Some of the cationic polymers also show high transfection 
efficiency but there is cytotoxicity associated with the high density of cationic charge.127-134–136 In 
spite of the early success of gene therapy, there still doesn’t exist a safe and efficient way of 
delivering nucleic acids.  
 The motivation behind our work on developing delivery carriers for nucleic acids was to 
tackle the issue of cytotoxicity that is inherent with the cationic polymers. In our design, we use a 
random copolymer comprising of the methylated pyridyl disulfide groups which makes the 
polymer positively charged and polyethylene glycol to increase the solubility of this polymer and 
improve the circulation time in serum.  The positively charged polymer can bind with negatively 
charged phosphate backbone of siRNA through electrostatic attraction. We then employ the 
crosslinking (reducing) strategy of the disulfide units.38-39-91 The process of crosslinking serves 
two purposes. Firstly, it incarcerates the siRNA in a physical mesh and secondly, it eliminates or 
		
	
110 
reduces the positive charge in the complex as shown in scheme 4.1, because the reactive 
methylated pyridyl group is cleaved as the byproduct of the crosslinking reaction. The disulfide 
network in the crosslinked system also provides an opportunity to release the siRNA once it 
reaches the cells due to the elevated amounts of glutathione in the cytosol.89-90 Overall, we have 
designed a safer delivery system, which is target specific and redox responsive.   
 
4.2 Results and Discussion 
4.2.1 Design and Synthesis  
 The precursor polymer is a random copolymer consisting of pyridyl disulfide ethyl 
methacrylate (PDSMEA) and polyethylene glycol side chains which was synthesized using RAFT 
polymerization. Polymer with different ratios of PDSMEA and PEG were synthesized to study the 
effect of charge density on the complexation efficiency with siRNA. After characterizing the 
polymer with 1H-NMR and Gel Permeation Chromatography, the precursor polymer was 
Scheme 4. 1 Schematic representation of complex formation between the cationic polymer and 
siRNA followed by crosslinking to eliminate the charged moiety. 
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methylated to introduce a permanent charge on the pyridine using methyl triflate. The methylation 
reaction was confirmed by 1H NMR where we observed an addition of the methyl peak at around 
4.4 ppm and a downfield shift of the aromatic protons.  
 
 
 
4.2.2 Complexation of siRNA with polymer 
 Polymers with different charge densities were synthesized to evaluate the effect of charge 
density on the binding efficiency with siRNA. It is well known that higher charge density helps in 
better electrostatic binding with siRNA.137–139 We also observed by Gel electrophoresis that the 
polymer with the highest positive charge density showed the most efficient binding with siRNA.  
 
Figure 4. 1 Methylation reaction of the PEG-PDS random copolymer 
characterized by 1H-NMR.  
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 The binding affinity of the polymer with siRNA was measured using Ethidium bromide 
fluorescence quenching assay. Ethidium bromide has been widely used as a fluorescent tag 
because it fluoresces once it intercalates in between the base pairs of nucleic acids including 
siRNA. However, in the presence of a polymer that can interact with the siRNA, the ethidium 
bromide gets excluded from the base pairs and loses its fluorescence. The polymer with 93% PDS 
was complexed with anti-luciferase siRNA with different mole ratios of polymer. This polymer 
was used for other studies unless mentioned otherwise. Ethidium bromide shows the maximum 
fluorescence intensity when treated with only siRNA as seen in Figure 4.3. With increasing molar 
ratio of the polymer, we observed a decrease in the fluorescence intensity of ethidium bromide as 
expected. Polymer without siRNA showed negligible fluorescence. This control had the same 
amount of polymer as the one with 130 moles excess sample.  
 We also measured the binding affinity of the polymer with siRNA using Gel retardation 
assay. In an Agarose gel matrix, in the presence of an electric field, negatively charged molecules 
migrate towards the positive electrode. The migration depends on the charge and molecular weight. 
Figure 4. 2 Optimization of N/P ratios between methylated PEG-PDS 
random copolymers and siRNA by increasing the molar ratio of methylated 
PDS unit characterized by gel electrophoresis. 
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siRNA moves towards the positive electrode because of the negatively charged phosphate 
backbone. Neutralization of the negatively charged siRNA by a cationic polymer prevents the 
migration of the siRNA. The migration is seen by Ethidium bromide fluorescence which is due to 
its intercalation in between the base pairs of nucleic acid. As seen in Figure 4.3 above N/P ratios 
of 50 we start observing some binding of the polymer with the siRNA as seen by the band in the 
well. The siRNA band completely disappears above N/P ratio of 65. 
 
Figure 4. 3 Relative binding affinity of 93% PDS polymer with siRNA as measured by – left: 
Ethidium bromide quenching assay and right: Gel retardation assay 
4.2.3 Size and morphology of the complex 
 Dynamic Light Scattering (DLS) was used to estimate the size of the complex formed 
between the polymer and anti-luciferase siRNA. The polymer or the siRNA by themselves are 
soluble in water and therefore do not form any aggregates as shown by the DLS data where the 
correlation function of both were very poor.  The complex however formed assemblies around 100 
nm with a strong correlation function. Transmission Electron Microscopy (TEM) images of the 
complex revealed spherical aggregates of about 100 nm which correlated with our DLS 
measurements. Both the DLS and TEM data taken together tells us that the complex formed are 
indeed spherical in solution as seen in Figure 4.4. 
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4.2.4 Redox Responsive Release 
 The disulfide bonds can be reduced in the presence of a reducing agent like Glutathione 
which is biologically significant as it is present at a significantly higher concentration inside the 
cytosol (millimolar) compared to the plasma (micromolar).90 After crosslinking the complex, the 
siRNA is incarcerated in the polymer network. However, once these disulfide crosslinks are 
reduced, the siRNA is expected to release because crosslinking results in the removal of the 
cationic moieties which was crucial in complexing with the siRNA. Redox responsive behavior of 
the crosslinked complex was monitored by Gel retardation assay. Release of the siRNA was 
observed when the crosslinked complex was incubated with 10 mM glutathione. There was 
negligible release seen for crosslink complex incubated with 10 µM glutathione or the crosslinked 
Figure 4. 4 Top - Size distribution of polymer, siRNA and the complex seen by Dynamic Light 
Scattering measurement; Bottom - Morphology of polymer, siRNA and complex as seen by 
Transmission Electron Microscopy. 
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and non-crosslinked complex incubated without glutathione. This suggests that the disulfide 
crosslinked complex is indeed responsive to higher concentrations of glutathione.  
 
 
 
 
4.2.5 Toxicity Assessment 
 We were interested in assessing the in vitro cytotoxicity of bare polymer. We tested the 
cytotoxicity of the polymer using Alamar blue assay on DU – 145, human prostate cancer cell line. 
After incubating the polymer with the cells for 24 hours at 37 °C, we observed high cell viability 
upto concentration of 0.5 mg per mL as shown in Fig. However, above that concentration there 
was toxicity observed. One of the future works of this chapter is to evaluate the cell uptake of 
FITC-siRNA complexed with polymer.  
Figure 4. 5 Glutathione responsive 
release of siRNA from the complex 
at different concentrations of 
Glutathione as seen by Gel 
electrophoresis. 
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4.2.6 Gene knockdown 
 It is essential to demonstrate the functional activity of siRNA after complexation with the 
polymer. Bright-Glo™ Luciferase assay (Promega) system was used to evaluate the efficiency of 
gene knockdown. Firefly luciferase catalyzes the oxygenation of luciferin the presence of ATP as 
co-factor and oxygen to produce luminescence.  Efficiency of transfecting anti-siRNA successfully 
into cells expressing luciferase is measured by its ability to suppress the luminescence production. 
Anti-luciferase siRNA was utilized to test the gene knockdown efficiency on DU-145 cells that 
express Luciferase. We first used Lipofectamine™ RNAiMAX as the transfecting agent to test the 
transfecting efficiency of anti-luciferase siRNA on the luciferase expressing DU-145 cell line. As 
seen in Figure 4.7, Lipofectamine was successfully able to transfect ant-luciferase siRNA on 
luciferase expressing DU-145. We tested the transfection under different siRNA concentrations, 
polymer concentrations, pre-and post-incubation time to optimize conditions for transfection. 
Figure 4. 6 Cell viability of the polymer on DU-145 cell lines as 
characterized by Alamar blue assay. 
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There was no transfection seen for - siRNA concentrations from 50 nM to 2 µM, pre-incubation 
from 6 to 24 hours and post incubation from 48 – 72 hours. Possible explanation behind this is the 
instability of the complex after complete crosslinking because of the loss of cationic charge which 
ascertains to be critical for binding with siRNA. Future work involves synthesizing polymer with 
cysteine which would provide charge in the final polymer. This is discussed in Chapter 5. 
 
 
Figure 4. 7 Luciferase knockdown assay for testing the transfection of anti-luciferase 
siRNA with a positive control Lipofectamine. 
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Figure 4. 8 Luciferase knockdown assay for testing the transfection of anti-luciferase siRNA 
complexed with the polymer by varying concentration of siRNA and the pre-incubation time. 
 
 
Figure 4. 9 Luciferase knockdown assay for testing the transfection of anti-luciferase siRNA 
complexed with the polymer by varying transfection time. 
4.3 Summary 
 We have designed a redox responsive cationic polymeric system that binds with siRNA 
through electrostatic interaction. Strategy to crosslinking the polymer-siRNA complex served two 
purposes – i) incarcerating the siRNA and ii) reducing the positive charge in the polymer. The 
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charged polymer which was hydrophilic formed a complex with siRNA of 100 nm size as observed 
by DLS and TEM. The crosslinked complex also showed redox responsive release when incubated 
with intracellular concentrations of Glutathione. Future work entails optimizing polymer design 
for stronger complexation with siRNA for transfection. 
4.4 Experimental Details 
4.4.1 Materials and Methods 
All the reagents were purchased from commercial source and used as such without further 
purification. Bright-Glo™ Luciferase assay system was purchased from Promega. Anti- luciferase 
siRNA was purchased from GE Dharmacon. 1H NMR spectra were recorded on a Bruker 400 MHz 
NMR spectrometer using the residual proton resonance of the solvent as the internal standard. 
Chemical shifts (δ) are reported in parts per million (ppm) and Hertz, respectively. The following 
abbreviations are used for the peak multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; dd, doublet of doublet; bs, broad singlet; bd, broad doublet; bm, broad multiplet. 13C-
NMR spectra were recorded on a 400MHz Bruker NMR spectrometer using carbon signal of the 
deuterated solvent as the internal standard. Dynamic Light Scattering (DLS) measurements were 
carried out on a Malvern Nanozetasizer. TEM images were recorded on a JEOL-2000FX machine 
operating at an accelerating voltage of 100 kV. Cell imaging was performed using a Zeiss 510 
META confocal microscope. Fluorescence measurements were performed on a fluorescence plate 
reader (Molecular Devices, SpectraMax M5). 
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4.4.2 Synthesis Procedures and Characterization of Molecules 
 
 
Synthesis of random copolymer 1 
 Pyridyl disulfide ethyl methacrylate (PDSEMA) monomer was synthesized according to a 
previous report. PDSEMA (272 mg, 1.06 mmol), Poly (ethylene glycol) methacrylate (28mg, 
0.056 mmol), 4-Cyano-4-(phenylcarbonothioylthio) pentanoic acid (8.418 mg, 0.0313 mmol) and 
AIBN (1 mg, 0.006 mmol) were weighed and dissolved with 400 µL THF in a 7-mL glass 
scintillation vial and sealed with a rubber septum. The flask was purged with argon followed by 
three freeze-pump thaw cycles. The reaction vial was then transferred to an oil bath preheated at 
65 °C. The polymerization was quenched after 24 h by cooling down the reaction flask with cold 
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water and the viscous reaction product was purified by precipitation in diethyl ether to yield the 
random copolymer as an off white solid. 
1H NMR: (CDCl3, 400 MHz), δ (ppm): 8.45 (1H), 7.68 (2H), 7.12 (1H), 4.22 (2H), 3.63 (2H), 3.37 
(0.2H), 3.02 (2H), 2.05-1.68 (2H), 1.06 (1H), 0.89 (2H). Integration of the methoxy proton (in 
PEG unit at 3.37 ppm) and the aromatic proton (in pyridine unit at 8.45 ppm) provided the molar 
ratio of two monomers. 
Synthesis of random copolymer 2 
Polymer 1 (216 mg, 0.8 mmol) was dissolved in 500 µL Dichloromethane in a 7-mL glass 
scintillation vial followed by the addition of Methyl trifluoromethanesulfonate (169 µL, 1.19 
mmol). The reaction was carried out for 4 hours followed by evaporating Dichloromethane in 
vacuo. The residue was dissolved in methanol and precipitated against diethyl ether three times to 
yield the product as an off white solid. 
 
Polymer 2 containing 93% PDS - GPC (DMF) Mn: 12.6 kDa. Đ: 1.2. 1H NMR: (CD3OD, 400 
MHz), δ (ppm): 8.9 (1H), 8.69 (1H), 8.53 (1H), 7.87 (1H), 4.52-3.98 (5H), 3.74-3.46 (2H), 2.04 
(2H), 1.44-0.86 (4H). 13C NMR: (CD3OD, 400 MHz), δ (ppm): 149.2, 145.9, 127.1, 125.9, 123.4, 
120.7, 118.2, 73.0, 71.6, 64.0, 47.1, 38.5, 27.4. 
 
Polymer 2 containing 80% PDS - GPC (THF) Mn: 9 kDa. Đ: 1.1. 1H NMR: (CD3OD, 400 MHz), 
δ (ppm): 8.9 (1H), 8.69 (1H), 8.53 (1H), 7.87 (1H), 4.52-3.98 (5H), 3.74-3.46 (9H), 2.04 (3H), 
1.44-0.86 (6H). 13C NMR: (CD3OD, 500 MHz), δ (ppm): 149.2, 145.9, 127.1, 125.9, 123.4, 120.7, 
118.2, 73.0, 71.6, 64.0, 47.1, 38.5, 27.4. 
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Polymer 2 containing 70% PDS - GPC (THF) Mn: 14.8 kDa. Đ: 1.1. 1H NMR: (CD3OD, 400 
MHz), δ (ppm): 8.9 (1H), 8.69 (1H), 8.53 (1H), 7.87 (1H), 4.52-3.98 (5H), 3.74-3.46 (8H), 2.04 
(2H), 1.44-0.86 (5H). 13C NMR: (CD3OD, 500 MHz), δ (ppm): 149.2, 145.9, 127.1, 125.9, 123.4, 
120.7, 118.2, 73.0, 71.6, 64.0, 47.1, 38.5, 27.4. 
 
Polymer 1 containing 85% PDS - GPC (THF) Mn: 8.5 kDa. Đ: 1.2. 1H NMR: (CDCl3, 400 MHz), 
δ (ppm): 8.45 (1H), 7.68 (2H), 7.12 (1H), 4.22 (2H), 3.63 (3H), 3.37 (0.4H), 3.02 (2H), 2.05-1.68 
(2H), 1.06 (1H), 0.89 (2H). Integration of the methoxy proton (in PEG unit at 3.37 ppm) and the 
aromatic proton (in pyridine unit at 8.45 ppm) provided the molar ratio of two monomers. 13C 
NMR: (CD3OD, 500 MHz), δ (ppm): 149.2, 145.9, 127.1, 125.9, 123.4, 120.7, 118.2, 73.0, 71.6, 
64.0, 47.1, 38.5, 27.4. 
 
Polymer 2 containing 90% PDS - 1H NMR: (CD3OD, 400 MHz), δ (ppm): 8.9 (1H), 8.69 (1H), 
8.53 (1H), 7.87 (1H), 4.52-3.98 (5H), 3.74-3.46 (2H), 2.04 (2H), 1.44-0.86 (4H). 13C NMR: 
(CD3OD, 500 MHz), δ (ppm): 149.2, 145.9, 127.1, 125.9, 123.4, 120.7, 118.2, 73.0, 71.6, 64.0, 
47.1, 38.5, 27.4. 
4.4.3 Other Experimental Protocols 
4.4.3.1 Dynamic Light Scattering (DLS) Study 
DLS was performed on a Malvern Nano-zeta sizer instrument with a 637 nm laser source 
with non-invasive backscattering technology detected at 173⁰. All sizes are reported as the 
hydrodynamic diameter (DH) and were repeated in triplicate. For the DLS measurements, the 
concentration of the polymer and nanogel solution was 1 mg/mL. The solution was filtered using 
a hydrophilic membrane (pore size 0.450 µm) before experiment was performed.   
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4.4.3.2 Transmission Electron Microscope (TEM) Study 
For the TEM measurements the nanogel solution was prepared in 1 mg/mL concentration. 
One drop of the sample (10 µL) was dropcasted on carbon coated Cu grid, 400 mesh size and left 
to dry overnight.  
4.4.3.3 In vitro Cell Viability 
The in vitro cellular viability of the nanogels was evaluated on DU-145 cell lines. The cells 
were cultured in T75 cell culture flasks using Dulbecco's Modified Eagle Medium/Nutrient 
Mixture F-12 (DMEM/F12) with 10 % fetal bovine serum (FBS) supplement. The cells were 
seeded at 10,000 cells/well/200 µL in a 96 well plate and allowed to grow for 24 hours under 
incubation at 37 °C and 5 % CO2. These cells were then treated with nanogels of different 
concentrations and were incubated for another 24 hours. Cell viability was measured using the 
Alamar Blue assay with each data point measured in triplicate. Fluorescence measurements were 
made using the plate reader SpectraMax M5 by setting the excitation wavelength at 560 nm and 
monitoring emission at 590 nm on a black well plate. 
4.4.3.4 siRNA – polymer complex formation 
Appropriate stock solutions of siRNA and polymer were first made in Ribonuclease 
(RNAse) free water to account for final polymer-siRNA solution to be 30 µL. siRNA stock was 
first added to a 100 µL Eppendorf tube followed by the addition of polymer solution. The mixture 
was vortexed for 10 seconds and incubated at room temperature for 60 minutes. The complexation 
between polymer and dsRNA was evaluated using electrophoresis on 2% agarose gel with 1x Tris 
-acetate-EDTA (TAE) running buffer at 72 V for 20 min.  
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4.4.3.5 Transfection and Luciferase assay 
 Dharmacon protocol for siRNA transfection was followed. Briefly siRNA - polymer 
complex solutions (check the above protocol for complex formation detail), polymer and siRNA 
control samples of desired concentration were prepared in RNAse free water to make up a total 
volume of 20 µL as control siRNA and polymer solution with the same concentration was used. 
After 30 minutes for complex formation, 80 µL of OPTI-MEMTM (antibiotic free) media was 
added to each sample to make up a total volume of 100 µL. Culture media was removed from cells 
grown on a 96 well plate at a density of 10,000 cells/well/100 µL and replaced with 100 µL of 
sample. The cells were incubated with the sample in OPTI-MEMTM for different time points and 
replaced with complete media for a total of 72 hours for protein analysis. 
 For Luciferase assay, 100 uL of Bright-Glo™ solution was added to each well consisting 
100 µL of media without replacement. The cells were incubated with Bright-Glo™ solution for 3 
minutes before analyzing for luminescence using the plate reader SpectraMax M5 with 1 second 
integration on each well.  
4.4.3.6 Crosslinking density 
In order to determine the crosslinking density, UV-vis measurements were performed with 
samples of the solution reacted with DTT. Once this was measured, we calculated the amount of 
pyridothione based on its known molar extinction coefficient (8.08 x 103 M-1 cm-1 at 343 nm).  
The percentage of cross-linking was calculated by assuming that formation of a single, 
crosslinking disulfide bond would require cleavage of two PDS units and produce two 
pyridothione molecules.                     
		
	
125 
 
4.4.4 1H- NMR 
*: solvent residues are marked with stars. 
 
Figure 4. 10 1H NMR of polymer precursor to 2 showing 93% PDS and 7% PEG. 
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Figure 4. 11 1H NMR of methylated polymer 2 constituting 93% PDS and 7% PEG 
 
		
	
127 
 
 
Figure 4. 12 1H NMR of methylated polymer 2 constituting 80% PDS and 20% PEG 
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Figure 4. 13 1H NMR of methylated polymer 2 constituting 90% PDS and 10% PEG 
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 Figure 4. 14 1H NMR of polymer precursor to 2 showing 85% PDS and 15% PEG. 
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Figure 4. 15 1H NMR of polymer precursor to 2 showing 85% PDS and 15% PEG. 
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4.4.5 13C- NMR 
 
 
 
 
 
Figure 4. 16 13C NMR of methylated polymer 2 constituting 93% PDS and 7% PEG. 
		
	
132 
 
 
 
Figure 4. 17 13C NMR of methylated polymer 2 constituting 90% PDS and 10% PEG. 
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Figure 4. 18 13C NMR of methylated polymer 2 constituting 85% PDS and 15% PEG. 
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Figure 4. 19 13C NMR of methylated polymer 2 constituting 80% PDS and 20% PEG. 
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Figure 4. 20 13C NMR of methylated polymer 2 constituting 70% PDS and 30% PEG. 
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4.4.6 Gel Permeation chromatogram 
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CHAPTER 5 
SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
 While designing therapeutic delivery vehicles for successful clinical translations, it is 
important to consider some key properties like target specificity, stimuli responsive release, 
biocompatibility, high drug loading ability and so forth.  This dissertation addresses this by 
designing delivery vehicles incorporating many of these essential characteristics.   
 In Chapter 2, we designed a crosslinked polymeric system based on ‘GRAS’ components, 
a term coined by the FDA to molecules that are safe to be used in food products, packaging and 
biomedical devices. The crosslinked polymer showed high in vitro cell viability and was non-toxic 
to mouse pre-implantation embryos. The crosslinked polymeric micellar aggregates were 
successfully able to encapsulate hydrophobic guest molecule and were responsive to intracellular 
concentrations of Glutathione.  
 In Chapter 3, we developed methods to quantify drug loading in crosslinked polymeric 
nanogels. The disulfide crosslinked nanogel showed high encapsulation efficiencies for different 
therapeutic drugs with varying LogP values. The drug encapsulated nanogels also showed efficient 
cell killing which was comparable with the free drug. We also attempted to study the structure 
property relationship between the different drugs with varying LogP values and the drug loading 
efficiencies 
 In Chapter 4, we designed a redox responsive polymeric system that binds with siRNA due 
to the positive charge of the methylated pyridine moiety. Strategy to crosslinking the polymer-
siRNA complex served two purposes – i) incarcerating the siRNA and ii) reducing the positive 
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charge in the polymer. The crosslinked complex also showed redox responsive release when 
incubated with intracellular concentrations of Glutathione.  
5.2 Future Directions 
5.2.1 Polyamide nanogels based on GRAS components as biocompatible nanocarriers 
 In Chapter 2, we were successfully able to design a functional polymer with Glutamic acid 
and 1,4 diaminobutane as the backbone. We are further interested in extending this system to other 
nucleic acids such that the degree of functionalization can be improved by eliminating the usage 
of another reagent in the polymer backbone. The specific aims of the project are -  
5.2.1.1 Synthesis of polyserine and polythreonine nanogel precursor using two different 
polymerization techniques 
5.2.1.1.1 NCA polymerization  
 Synthesis of polyserine and polythreonine will be achieved by reacting commercially 
available γ-benzyl-L-Serine/Threonine with triphosgene to form α-aminoacid-N-
carboxyanhydride (NCA, 1), Fifure 5.1 which will then be polymerized through ROP to form 
poly(γ-benzyl-L-aminoacid). The benzyl protecting groups on poly(γ-benzyl-L-aminoacid) will 
then be removed by HBr to yield 2. PEG and PDS will be introduced to the polymer by making 
their NHS (N-hydroxysuccinimide) esters and reacting them with the alcohols in the polymer 
backbone to give the product 3.  
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5.2.1.1.2 Self condensation polymerization 
 Boc protected serine/threonine,4, Figure 5.2 will be polymerized via self-condensation 
method to yield 5 followed by the deprotection of amine using trifluoro acetic acid (TFA) and 
further reacting the amine with PDS and PEG NHS to yield the polymer 6, 
 
5.2.1.2 Degradation 
 The polymers synthesized through the two polymerization techniques afford a polyamide 
and a polyester backbone. It will be interesting to investigate and compare the degradation rates of 
both. 
Figure 5. 1 Reaction scheme for NCA polymerization of serine and threonine 
Figure 5. 2 Reaction scheme for self-condensation polymerization of Serine and Threonine 
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5.2.1.2.1 Hydrolytic degradation 
  The stability of the amide and ester backbone of the polymer to hydrolysis under 
physiological conditions will be evaluated. The polymer will be incubated in buffer at 37oC at pH 
7.4, 6.5, 5, and 4 to examine the relative stability or degradation in the biological pH of circulation, 
tumor tissue, endosome, and lysosome. The samples will be evaluated over time with 1H-NMR, 
GPC and fluorescamine assay. 
5.2.1.2.2 Enzymatic degradation 
 Degradation due to enzymatic hydrolysis of the nanogels should generate compounds 
having primary amino groups. Thus, fluorescamine assay is a promising method to evaluate the 
degradation. 
5.2.2 Crosslinked block copolymer nanogels for drug delivery and methods to quantify 
drug loading in crosslinked nanogels 
5.2.2.1 Viscosity of PEG 
   In chapter 4 we designed redox responsive crosslinked block copolymers for high drug 
loading. One of the key observation was that the crosslinking efficiency was poor for block 
copolymers with longer PEG chains. One of the hypothesis for this phenomenon is attributed to 
the viscosity of longer PEG chains as this could affect the diffusion of molecules.  It is known that 
the viscosity of PEG solutions increases with an increase in the molecular weight of PEG, Table 
5.1.97-98 We want to investigate this by varying PEG concentration and PEG length and measure 
the viscosity using rheometer.  
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5.2.2.2 Crystalline packing of OEG 
 We recently observed for nanoparticles prepared using inverse emulsion methodology 
consisting of disulfide crosslinks and oligo ethylene that the redox sensitivity for nanoparticles 
with longer OEG chains was less efficient that nanoparticles with smaller OEG chains. This was 
attributed to the crystalline ordering observed in nanoparticles with longer OEG chains as 
evidenced by Cryo-electron microscopy and electron diffraction pattern. Crystalline ordering of 
PEG chains could hinder the diffusion of small molecules which could affect the crosslinking 
efficiency. It would be interesting to investigate the possibility of crystalline ordering in our block 
copolymers consisting of PEG using Cryo-electron microscopy and electron diffraction pattern.  
5.2.2.3 Varying the hydrophobic block 
 Crosslinking the block copolymer using DTT results in removal of pyridothione which in 
turn reduces the hydrophobicity of the core. Varying the hydrophobic section by 
adding/substituting PDS moieties with different alkyl/aromatic units would be interesting in 
studying the drug loading properties and the crosslinking efficiencies. This will be achieved by 
Table 5. 1 Viscosity value of 
polyethylene glycol with varying 
Molecular weight 
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introducing hydrophobic monomers by post functionalization or during polymerization as shown 
in Figure 5.3. 
 
 
Figure 5. 3 Reaction scheme for introducing hydrophobic side chains via - above: post 
functionalization; below: polymerization. 
 
5.2.2.4 Drug release  
 Evaluating kinetics of drug release from nanoparticles with different crosslink densities is 
essential. Although we did not observe a trend in the in vitro cell viability assays, it would be 
important and interesting to monitor drug release ex vivo.  
5.2.2.5 Biodistribution of drug loaded nanoparticles 
  The polymer would be covalently labeled with a fluorophore for imaging. The 
nanoparticles would be administered in mice intravenously. Different organs of the mice would be 
dissected at different time points for imaging to determine the biodistribution of these 
nanoparticles in vivo.  
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5.2.3 Charge-tunable, redox responsive polymeric nanocarrier for siRNA delivery 
5.2.3.1 Modified design 
 We observed that complexation of the polymer with siRNA was not as strong when we 
increased the crosslink density. This could be due to the elimination of the charged moiety during 
crosslinking reaction. We propose a new design where a percentage of the PDS side chain is 
replaced with cysteine to introduce charge in the final polymer (after 100% xlinking). Cysteine is 
naturally occurring amino acid which is semi-essential and hence is biocompatible, 
 
 
 
5.2.3.2 in vitro cell uptake 
 FITC labelled siRNA will be utilized for complexation with polymer and the cell uptake 
will be monitored over a time period of 2h, 4h, 6h, 12h and 24h using confocal microscopy.  
5.2.3.3 Mouse preimplantation embryo model 
 Nucleolar protein 2 (NOP2) is an essential protein during mammalian preimplantation 
development. It has been reported that knockdown of NOP2 arrests blastocyst formation.140 siRNA 
against NOP2 would be used to evaluate functional activity of the polymer complex in vivo. 
Embryo development will be monitored at each stage – 2 cell, 4/8 cell, morula and blastocyst.  
 
Figure 5. 4 Reaction scheme for introducing Cysteine in the random 
copolymer 
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